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Abstract
The ribosome is one of the most basic cellular machines and is ubiquitous in all living cells, re-
sponsible for the translation of genes into functional proteins. The central task of the ribosome
is to promote peptide-bond transfer reaction by precisely aligning substrates of protein synthesis
in ribosomal peptidyl-transferase center (PTC). To guarantee translation fidelity and cell survival,
protein synthesis by the ribosome is tightly controlled by cofactors and a range of biological pro-
cesses. In this thesis, we aim to investigate four translational control mechanisms that bring the
ribosomal PTC into focus: (1) abolishment of ribosomal translation by the antibiotic action of
macrolide drugs. (2) programmable translation arrest modulated by regulatory nascent peptides.
(3) ribosomal discrimination of the chirality of amino acids within PTC. (4) translational control
by EttA (energy-sensing translational throttle A) under energy-depleted cellular conditions. We
employ computational approaches and collaborate closely with experimentalists. Our joint efforts
advanced the understanding of translational control by the interplay of ribosome and cofactors. Our
results may promote novel design of next generation antibiotic drugs because the bacterial ribosome
is the main antibiotic drug target.
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Chapter 1
Introduction
1.1 Protein factory in the ribosome
Figure 1.1: The simplified four-step translation cycle of the ribosome.
The ribosome, an RNA-protein
complex [1], is one of the most
complex and ubiquitous molec-
ular machines in living cells, re-
sponsible for the critical task
of translating the genetic code,
carried on the mRNA, into
functional proteins [2, 3]. As
shown in Fig. 1.1, the ribosome
composes of a large subunit
(Cyan) and a small subunit
(Yellow), which together con-
struct three consecutive cavi-
ties, the aminoacyl-tRNA binding (A) site, the peptidyl-tRNA binding (P) site and the tRNA
exit (E) site. The translation cycle summarizes the processes by which new amino acid are chained
to the nascent polypeptide, which egresses through the exit tunnel of ribosomal large subunit on
the way to cellular cytoplasm. First, to initiate translation, large and small ribosomal subunits
assemble and sandwich the mRNA strand together with a P-site tRNA charged with an amino acid
fMet, called initiator tRNA [4], which is always the first amino acid in a nascent polypeptide. The
coming aminoacyl-tRNA charged with a correct amino acid, matching genetic information carried
on the mRNA, is accepted by ribosome to the A site. Second, a peptide bond is formed between the
P-site C-terminus of the nascent polypeptide and the A-site amino acid and the nascent polypep-
tide is transfered to the A-site tRNA so the P-site tRNA becomes deacylated, an important process
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Figure 1.2: Ribosomes from different species share a common RNA core but differ at the outer ribosomal protein and
RNA extensions.
called peptide-bond transfer. Third, P-site deacylated-tRNA and A-site peptidyl-tRNA together
with mRNA shift towards the E site, during a process called translocation [5–7]. At the end of the
third step, the peptidyl-tRNA is in the P site and the deacylated-tRNA is in the E site. Finally, the
E-site deacylated-tRNA leaves ribosome and the P-site nascent polypeptide is ready to take a new
amino acid. The translation cycle continues until the whole nascent polypeptide, whose sequence is
encoded in the mRNA, is synthesized.
1.2 The central task of the ribosome
The central task of the ribosome is to catalyze the peptide-bond transfer in peptidyl transferase cen-
ter (PTC), which is the core region in the large subunit between the A and P sites. Although atomic
models of ribosomes from different species show large structural differences at the outer extensions
of ribosomal proteins and ribosomal RNAs (rRNAs) (Fig. 1.2), they share a universally conserved
PTC core [1, 8, 9]. The structure of ribosomal PTC is entirely constructed by highly-conserved
RNA nucleotides in all species [10]. The ribosome increases the rate of peptide-bond transfer by
at least 105 fold [11]. Early investigations suggested that the ribosome catalyzes the peptide-bond
transfer directly through chemical catalysis [10, 12]. However, more studies, including more recent
ones, have shown that the ribosome promotes peptide-bond transfer mainly by precisely positioning
the substrates of protein synthesis [13–15], i.e. the ribosomal PTC is a structural template in which
the P-site peptidyl-tRNA and A-site aminoacyl-tRNA can be aligned in an configuration that is op-
timal for peptide-bond transfer. In addition to aligning substrates, which is the main contribution
2
Figure 1.3: The precision positioning of ribosomal nucleotides in the PTC align A- and P-site substrates to assume
proper conformation for peptide-bond formation. The structure shown here was determined by crystallography [23]
(PDB ID: 2wdk, 2wdl).
to catalysis of peptide-bond transfer by the ribosome [14, 16], some ribosomal structures in the PTC
may also alter the transition path for the reaction of peptide-bond transfer [17, 18], however, the
major contribution for the increase of the reaction rate is entropic [16, 19]. The ribosome achieves
the precise alignment of substrates through a rigid backbone of RNA helices in the PTC, which do
not easily alter conformations when substrates of protein synthesis, including mimic of intermedi-
ate state of peptide-bond transfer, are bound [15] or even when a variety of antibiotic drugs are
bound [20]. The PTC backbone structure provides a consistent template to align substrates in a
precise spatial arrangement which promotes peptide-bond transfer [15, 21, 22] (Fig. 1.3).
1.3 Translation control by ribosome and cofactors
Gene expression and ribosomal protein synthesis are essential cellular processes that are tightly
controlled at multiple levels in living cells. While most regulation aims at the initiation step to
identify the AUG start codon and assemble the initiation complex, which involve the initiation
factor [24–26], many cofactors such as the elongation factor [27, 28] and the release factor [29] are
recruited in the ribosomal translation cycle for the purpose of translational fidelity and efficiency.
Recent efforts also uncovered the role of nascent peptide in regulation of translation arrests [30–33]
or gene expression [34, 35], protein folding [36, 37] and localization [38]. Drug molecules may also
be translational control cofactors. For example, it is critical for the survival of bacterial cells to
expression resistant genes with the presense of antibiotic drugs [39, 40]. Translational control are
also essential for cell survival and growth-reinitiation under stress conditions [41–43].
3
1.4 Summary of investigation topics
In this thesis, the ribosomal PTC is brought under focus as the target of translational control by the
ribosome. First, we show that binding of macrolide drugs may predispose the ribosome for transla-
tion by changing structures of the PTC, which is a revolutionary view about the antimicrobial action
of the most widely-prescribed antibiotics, the macrolide family. Second, we show that engineered
point mutation on the regulatory leader peptide of drug-resistant proteins can be used to modulate
translation arrest and control drug resistance, which opens a new possibility to fight the global crisis
of antibiotic resistance [44]. Third, we show that the ribosome also selects amino acids by their
correct chirality, which provides new insights into the regulatory role of the interplay between the
nascent peptide and the ribosome to assure translation fidelity. Finally, we show that under energy-
depleted conditions, represented by an ADP-rich cellular conditions, a newly characterized ABC-F
protein [45] the energy-sensing translational throttle A (EttA) may inhibit the first peptide-bond
formation inside the ribosome to turn the translation machinery into hibernation, which provides
insights into mechanisms of cell survival under energy starvation. Molecular dynamics (MD) simu-
lations and molecular dynamics flexible fitting (MDFF) computations (See Appendix A) are the
key methods to describe the detailed structural and dynamic mechanisms underlying the above-
mentioned translational control processes. Close collaborations with experimental teams allow us
to verify hypothesis raised by computational investigations and advance scientific discoveries. The
added value of computation to guide and elucidate experiments are also demonstrated, especially in
the cases that the joint efforts of experiments and computation discovered a new antibiotic action
and a new engineering technique to modulate antibiotic resistance.
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Chapter 2
Antibiotic action of macrolide
antibiotics
Reproduced in part with permission from S. Sothiselvam, B. Liu, W. Han, D. Klepacki, G. C. Atkinson, A. Brauer, M.
Remm, T. Tenson, K. Schulten, N. Va´zquez-Laslop, and A. S. Mankin. Macrolide antibiotics allosterically predispose
the ribosome for translation arrest. Proc. Natl. Acad. Sci. USA, 111:9804-9809, 2014. Copyright 2014 The National
Academy of Sciences of the USA.
2.1 Introduction
Figure 2.1: The macrolide drugs (for example, erythromycin) bind to the ri-
bosomal nascent protein exit tunnel (NPET) at ribosomal nucleotide A2058,
which is a remote site to the peptidyl transferase center (PTC) represented
by ribosomal nucleotides U2585 and A2602. The chemical structures of ery-
thromycin and telithromycin are shown in diagram representation and not-to-
scale with the schematic ribosome.
It is well-known that proteins
are the work-horse of living
cells. They carry out most
essential cell functions [46].
Without being able to make
proteins, most cells would not
be able to carry their day-to-
day functions at all. The ma-
jority of antibiotics [47] take
advantage of this fact to kill
bacteria by an attempt to pre-
vent bacterial cells from mak-
ing their proteins. The ribo-
some is the protein factory in
all living cells, therefore, it be-
comes the key target of antibiotic drugs [47], including the clinically important macrolide antibi-
otics [48]. Macrolide drugs are perhaps the most widely used prescriptions to fight maliciously
bacteria to the extent that they are listed on the WHO essential medicines list [49, 50]. The an-
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tibiotic action of macrolide drugs have been discovered for over 60 years, however, the mechanisms
underlying how the drugs work at the molecular level is still considered, to a large extent, as a
myth [51].
Macrolides, from the prototype erythromycin to the newest macrolide derivatives-ketolides, e.g.,
telithromycin -bind in the bacterial ribosomal nascent protein exit tunnel (NPET) at a short distance
from the peptidyl transferase center (PTC) [20, 52–54] (Fig. 2.1). When a nascent peptide grows to
4-7 amino acids, it reaches the site of antibiotic binding and has to negotiate the drug-obstructed
ribosomal exit tunnel aperture. Subsequent events depend on the properties of the nascent chain [34,
55, 56]. Although for many proteins the encounter of the peptide with the antibiotic results in
peptidyl-tRNA dropoff, the N-termini of certain nascent peptides can bypass the antibiotic [34].
Translation of some of such proteins can be arrested at specific sites within the gene, resulting in
formation of a stable stalled complex [34, 57]. Such translation arrest defines the role of macrolides
as cofactors of programmed ribosome stalling [34, 39, 55, 56].
It was previously believed that the presence of the nascent chains in the NPET was necessary
for the stalling action of macrolide drugs: the drug either passively impedes the elongation of the
nascent chain [58–62], or the interaction among the drug, the nascent chain and the ribosome is
critical for halting translation [39, 63].
The nascent chains which are able to induce translation arrest are characterized by their leader
regulatory peptides, the presense of which in the NPET may trigger the expression of drug resistance
genes. Those leader regulatory peptides have been classified by the structure of their known or
presumed stalling domains [64, 65]. The first and second class contains the ErmAL and ErmCL
leader peptide, respectively [64, 65]. Translation of ErmAL and ErmCL peptides is arrested after
the ribosome has polymerized the 8-amino acids (ErmAL1) or 9-amino acids (ErmCL) long nascent
chains that carry the C-terminal stalling domains Ile-Ala-Val-Val (IAVV) and Ile-Phe-Val-Ile (IFVI),
respectively [39, 66, 67]. The 8-9-amino acids long ErmAL1 or ErmCL stalling peptides reach far
into the ribosomal exit tunnel and must be juxtaposed with the antibiotic molecule in the ribosomal
exit tunnel; such apposition has been suggested to play a key role in the mechanism of the translation
arrest [39]. This view agrees with the strict structural requirements of the macrolide cofactor in
which removal or modification of the C3 cladinose abolishes stalling, possibly by disrupting drug-
peptide interactions [40]. For the above two classes, the N-terminal segments are required for
translation arrest [39]. Furthermore, the position of the IAVV and IFVI for the first and second
classes, respectively, must be at the C-terminus to induce translation arrest [39, 66, 67]. The third
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class involves the presense of the much shorter Arg-Leu-Arg (RLR) motif in their sequence [64].
In striking contrast to the first and second classes, in the third class the placement of the RLR
motif within these peptides is highly variable [64], which inspires us to test a novel hypothesis that
a nascent chains containing only the RLR motif can induce translation arrest even if it cannot
reach the macrolide binding site and therefore interact with the drug directly. More interestingly,
if translation arrest does not need the drug to interact with a regulatory leader peptide directly, it
may not need the presence of a regulatory leader peptide at all, which means that the antibiotic
action of macrolide drugs can directly induce an effect on the ribosome.
In this chapter, we show that the antibiotic induces stalling, even without the presence of a
regulatory leader peptide, by allosterically altering the conformation of the ribosomal PTC. This
finding unveils a previously unknown role of cofactors for translation arrest and demonstrates a
direct antibiotic action on the ribosome by macrolide antibiotics.
2.2 Results
2.2.1 Dispensable nascent peptide for the induction of translation arrest
Once the translation cycle (Fig. 1.1) is started, translation arrest can be induced by inhibition
of either the peptide-bond formation, which involves the ribosome PTC, or translocation, which
involves the relative motion between two ribosomal subunits. Both mechanisms of stalling the
translation require intricate interplays of structural elements at the interface of the two ribosomal
subunits [1]. However, macrolide antibiotics bind at the NPET [20, 52–54], which is about 10 A˚ away
from the ribosomal subunit interface and the PTC (See Fig. 2.1). This fact is the major evidence
used to support the conventional view that the nascent peptide must be present for macrolide
drugs to take antibiotic effects [39, 58–63]. However, here we showed that the nascent peptide is
dispensable for macrolide antibiotic to induce translation arrest.
By progressively truncating the N-terminus of RLR-containing nascent peptides, our experi-
mental collaborator, the Mankin Lab (U. Illinois at Chicago), demonstrated that the N-terminal
segment of RLR-containing peptides are dispensable for drug-dependent stalling [68] and that bind-
ing of ERY to NPET can trigger translation arrest when the nascent chain is as short as a three
amino acids-long peptide (MRL) [68].
Since a three amino acids-long peptide is too short to reach the canonical drug binding site for
macrolide antibiotics, there are three possible causes that may account for the experimental finding
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Figure 2.2: erythromycin is stably bound in NPET. (A) Center of mass (COM) displacement plots for the ery-
thromycin molecule in the tRNA-free ribosome during three independent simulation runs show no tendency for the
antibiotic to relocate from its tunnel site. The COM displacement is measured between the COM of ERY in MD
simulations and its COM in the crystallographic structure with the Protein Data Bank ID code 3OFR. (B) Selective
2’-hydroxyl acylation analyzed by primer extension (SHAPE) probing of the accessibility of A2058 in the ERY binding
site in the vacant ribosome or in the ribosome that has synthesized the MRL tri-peptide in the cell-free translation
system. Note that A2058, which is modified readily by the 1M7 reagent in the absence of ERY, is similarly protected
by the antibiotic in the vacant or in the MRL-stalled ribosome. (C) The relative placement of ERY in the NPET
and U2585 in the PTC in the crystallographic structure of the E. coli ribosome-ERY complex [53] (PDB ID code
3OFR). Residues A2058 and A2059 in the ERY binding site are also shown. (D) The nascent MRL tripeptide barely
reaches the antibiotic in the NPET and cannot be juxtaposed with it. The P-site MRL-tRNALeu(blue) and A-site
Arg-tRNAArg(green) were modeled into the structure of the E. coli ribosome-ERY complex and subjected to 2 ns
equilibration to avoid immediate structural clashes.
mentioned above. Firstly, the ribosome NPET structures can replace the role of a juxtaposed nascent
peptide and connect the drug binding site and the ribosomal PTC, relaying information about drug
binding just as the nascent peptide does [39, 63]. Secondly, interaction between the antibiotic and
the regulatory leader peptide is still necessary but the antibiotic is able to relocate to reach the short
peptide at the PTC, which is about 10 A˚ away from the drug binding site (See Fig. 2.2C). Lastly,
the binding of the antibiotic could still deliver the antibiotic action, i.e. stalling the translation by
affecting remote ribosomal PTC, in a previously unknown way, without interacting with a regulatory
leader peptide.
Our experimental collaborator demonstrated that none of the known nascent peptide ribosomal
sensors in the NPET are involved in drug-induced stalling with the short MRL peptide [68], which
excluded the first possible cause mentioned above. To test the second possible cause, we measured
the center of mass (COM) displacement of ERY using samplings of sub-microsecond equilibrium MD
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simulations and found that the drug is stably bound in the NPET; the largest displacement observed
during simulations is less than 1 A˚ (See Fig. 2.2A), which means that the drug is unlikely to be
able to relocate after binding. To verify our computational result. Our experimental collaborator
performed SHAPE [69] protection experiments about the drug binding site in either an vacant
ribosome or a ribosome with the MRL peptide [68]. In both cases, ribosomal nucleotide A2058 is
well protected [68], which means that the presense of the MRL peptide is not relevant in affecting the
location of the drug and the drug is located firmly at the binding site (See Fig. 2.2B). Furthermore,
in a non-vacant ribosome, i.e. a ribosome with a nascent peptide and tRNAs, molecular modeling
also showed that the ERY drug is unlikely to reach the MRL peptide (Fig. 2.2D).
By ruling out the above-mentioned two possible causes, it turns out that the only feasible mecha-
nism underlying the antibiotic action of the macrolide drug is that the nascent peptide is dispensable
to induce translation arrest and a new mechanism underlying the macrolide antibiotic action is to
be discovered, namely, the antibiotic can inhibit the ribosome’s ability to catalyze peptide-bond
formations without a regulatory leader peptide present in the NPET.
2.2.2 Macrolide-induced ribosomal nucleotide base flipping
A distance of more than 11 A˚ separates the nearest atom of the tunnel-bound macrolide antibiotic
(ERY, TEL, or solithromycin (SOL)) from the PTC active site [53, 54]. Hence, macrolides cannot
prevent peptide bond formation by direct steric hindrance unless the peptide induces relocation of
the drug to the PTC, which we view as an implausible scenario (See Fig. 2.2). Furthermore, the
short length of the MRL peptide makes it unlikely that the drug forces it into a nonproductive
conformation, as was proposed for the longer stalling peptides [39, 40]. Therefore, we hypothesized
that binding of the drug in the NPET may allosterically influence the structure, and hence the
function, of the PTC.
Our experimental collaborator performed chemical protection experiments with drug-free and
ERY-bound ribosomes [68]. Protections of some nucleotides, such as A2058 and A2059 at the drug
binding site, are expected because these residues interact directly with the drug. Strikingly, however,
modification of the distant U2585 in the PTC also was reduced significantly in response to ERY
binding [68]. Other macrolide drugs, such as SOL and azithromycin (AZI), had a similar effect
on the U2585 reactivity [68], suggesting a reliable response of U2585 to the binding of macrolide
drugs. U2585 is located in the PTC active site and is critically involved in catalysis of peptide bond
formation [15, 23]. This finding fits well with our hypothesis that the macrolide drug binding can
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Figure 2.3: Equilibration of the ribosome structure and conformations of U2585 and A2602 rRNA residues during
MD simulations. (A) The changes in the orientation angle of U2585 over simulation time. The orientation angle
is defined as in Fig. 2.4B,C. ERY1, ERY2, and ERY3 are independent simulations of the ERY-bound ribosome.
Drug-free1, Drug-free2, and Drug-free3 are independent simulations of the drug-free ribosome. (B) Same as A, but
for A2602. (C) Average orientation angles of U2585 and A2602 during the last 50-ns simulations (A˚+ SD). (D)
The rmsd-vs.-time plot for nonhydrogen atoms shows the progress of reaching stable equilibrium during the all-atom
ribosome MD simulations. Drug-free and ERY-bound ribosome structures were aligned to reference crystallographic
structures 2AVY/2AW4 and 3OFO/3OFR, respectively, and rmsd values were calculated between simulation frames
and the corresponding reference structures [2AVY/2AW4 (1) for the drug-free ribosome and 3OFO/3OFR (2) for the
ERY-bound ribosome]. All nonhydrogen atoms within 40 A˚ of U2585 in each system were considered in the rmsd
calculations. Note that all simulations started with a similar initial conformation (Fig. 2.5).
induce conformational change of the PTC and, therefore, abolish the ribosome’s catalytic property.
To reveal the molecular details of the functional link between the presense of a drug molecule in
the NPET and conformational change at the PTC, we performed large-scale MD simulations of
drug-free and ERY-bound ribosomes using the Blue Waters supercomputer [70].
We carried out all-atom MD simulations of the drug-free and ERY-bound E. coli ribosome on
the bases of the corresponding crystallographic structures [71, 72]. Six independent simulations,
three with the drug-free and three with the ERY-bound structure, were performed for the entire
ribosome (about 3 million atoms), with production simulation time in each run ranging from 70 to
273 ns. After the preproduction equilibrations, the starting structures of both models show very
similar conformations at the PTC region (See Fig. 2.5A).
Consistent with the crystal structures [54], MD simulations showed that the presence of ERY
affects the placement of its immediate neighbor A2062 (Fig. 2.4A). Most notably, the presence of
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Figure 2.4: MD simulations substantiate the allosteric effect of the NPET-bound ERY on the distant PTC nucleotides
U2585 and A2602. (A) Root mean square deviation (rmsd) of the preferred positions of rRNA residues in drug-free and
ERY-bound ribosome. The rmsd was calculated by averaging the last-frame coordinates of the residues in three inde-
pendent simulations of drug-free and ERY-bound ribosome. (B, Left) The frequency of visiting various conformations
by U2585 in the course of MD simulations of drug-free (green) or ERY-bound (blue) ribosome [presented as angles
between vectors linking atoms U2585(C3’)/U2585(C4) and U2585(C3’)/G2608(C3’) (Inset)]. (Right) Placement of
U2585 in drug-free (green) and drug-bound (blue) ribosomes. The averaged last-frame positions of the residues are
shown. The shortest distances between the drug and U2585 base in two states are indicated. (C) Same as B but for
the residue A2602.
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Figure 2.5: Molecular dynamics (MD) simulations illuminate the existence of a structural link between the nascent
peptide exit tunnel (NPET) and the peptidyl transferase center (PTC). (A) The conformation of the NPET and
PTC rRNA residues of drug-free (green) and ERY-bound (blue) ribosomes are similar after the initial preproduction
equilibration. (B) During production simulations, the ERY-proximal A2062 in the NPET and distant U2585 and
A2602 in the PTC tend to adopt different conformations. The figure shows the last-frame position of the nucleotides
averaged over three independent simulations. Green, drug-free ribosome; blue, ERY-bound ribosome. (C) The looped-
out conformation of U2585 and A2602 in the drug-free ribosome sometimes can be stabilized by possible stacking
interactions between the two residues. (D) Possible conformational relay routes connecting the macrolide molecule in
the NPET to the PTC. The pathway initiated at A2062 is shown in cyan, and the one starting at U2609 is orange.
U2585 in the PTC active site is red. The mutations of A2062, U2609, U2586, or U1782 do not abrogate translation
arrest controlled by antibiotic and the MRL peptide.
antibiotic also affects two remote sites in the PTC (Fig. 2.4). In excellent agreement with the
results of chemical probing [68], the drug promotes a dramatic reorientation of U2585 (Fig. 2.4B).
Although in the absence of antibiotic the nucleotide stably populates a looped-out configuration,
ERY prompts rotation of the U2585 base by 100o (Fig. 2.4B, Fig. 2.5B and Fig. 2.3A) This new
folded-in state of U2585 is stabilized by its stacking interaction with U2584 and U2586 (Fig. 2.6). In
two of the three simulations of the drug-bound ribosome, U2585 rotation occurred within 50 ns after
the start of the production simulation and remained in this orientation most of the time thereafter
(Fig. 2.3A,C). In the third simulation, the folded-in state of U2585 was not fully achieved, but the
U2585 base had rotated toward the folded-in position on average by 10o (Fig. 2.3A,C) In contrast,
in three simulations of the drug-free ribosome, the U2585 base barely visited the folded-in state (a
total of 418 ns of the combined simulation time) and instead populated the looped-out conformation
(Fig. 2.3A and 2.5B).
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A second, even more distant PTC residue, A2602, was also sensitive to the binding of ERY. The
preferred orientations of the A2602 base in drug-free and ERY-bound states differ by 110o (Fig. 2.4C).
Although in the absence of the drug A2602 is in a looped-out state away from helix 93 of 23S rRNA,
the antibiotic provokes insertion of the base into the helix concomitant with its local distortion
(Fig. 2.4A and C, Fig. 2.3B and C). Taken together, the results of the full-ribosome MD simulations
provide support with atomic detail for an antibiotic action of the macrolide drug at the NPET to
the ribosomal PTC active site.
2.2.3 Molecular details underlying macrolide-induced ribosomal base
flipping
Demonstrated by MD simulations and verified by chemical protection experiments [68], the highly
conserved and catalytically critical ribosomal nucleotides U2585 [15, 23] and A2602 [29] clearly
favor the folded-in conformation (See Fig. 2.4 and Fig. 2.6). The Generalized Born [73] (GB)
interaction energy between either U2585 (Fig. 2.6A) or A2602 (Fig. 2.6C) and their neighborhood
suggested the folded-in state of the two nucleotide lowers the system energy. Strong neighborhood
stacking interactions of U2585 contributed to stabilize the system (Fig. 2.6B). Most interestingly, the
cladinose ring of ERY interacted with U2609 and A1782 and stacking of the three entities contributed
to stabilize the neighborhood and helped alignment of U2584 to U2586, forming a stable stacking
configuration (Fig. 2.6B). By contrast, when U2585 was in the looped-out conformation, no strong
stacking configurations were found at U2585’s neighborhood, in which case, U2609 is hydrogen-
bonded with A752 as in the canonical drug-free ribosome [23].
2.3 Discussion
2.3.1 A novel view of antibiotic action
The common view of the mechanism of antibiotic- and nascent peptide-controlled translation arrest
presumes the key role of molecular interactions at the interface of the drug and the nascent chain [39,
58–63]. The juxtaposition of the peptide and antibiotic brings the stalling domain into contact with
tunnel sensors, which relay the signal to the PTC, impairing its functions [39, 67, 74, 75]. Although
such a view is sufficient to rationalize the mechanism of arrest with long regulatory peptides, it
fails to explain how an antibiotic can promote arrest with the only 3-amino acid-long MRL peptide.
Furthermore, the tolerance of such arrest to alterations in antibiotic structure or to the mutations
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of the known nascent peptide sensors [68] does not fit with the conventional view.
Our findings, however, may be reconciled within the framework of an alternative, potentially
complementary model whose centerpiece is the allosteric link between the tunnel and the PTC.
Binding of antibiotic in the tunnel alters properties of the PTC and inhibits peptidyl transfer
catalysis between certain donor and acceptor substrates. Therefore, the tunnel-bound small molecule
predisposes the ribosome for stalling when such combinations of substrates are encountered during
translation.
2.3.2 Nucleotide base flipping in ribosomal PTC
The results of our biochemical testing and MD simulations clearly show that the binding of an
antibiotic in the NPET alters the structural and thus likely functional features of the PTC. The data
are most consistent in regard to the universally-conserved U2585, a key residue in the PTC active
site required for aligning tRNA substrates to prepare peptide-bond formation [13, 15, 23, 76]. The
reactivity of this residue to the SHAPE reagent is altered when the antibiotic is bound in the tunnel.
It also is one of the PTC residues that in the MD simulations reorients most dramatically in response
to ERY binding and adopts a conformation rarely visited in the drug-free ribosome. The movement
of U2585 seemed to be accompanied by repositioning of A2602 (Fig. 2.4C and Fig. 2.5B). Although
chemical probing did not provide additional evidence for rearrangements of A2602, its ERY-induced
movement is supported by crystallographic structures of antibiotic-containing complexes, in which
it was modeled in a conformation different from that in the drug-free ribosome [20, 54]. A2602 is
also a universally-conserved nucleotide at the PTC. It is an important nucleotide for catalysis of
polypeptide release [29].
In RNA molecules, single base bulge, such as U2585 and A2602 in the ribosome, is a relevant
motif for RNA-ligand binding or to form tertiary structure formations [77, 78]. When nucleotides
U2585 and A2602 are in the folded-in state, buried in ribosomal Helix 93, the two nucleotides
are not available for the task of precise alignment of tRNA substrates. Drug-induced nucleotides
flipping of U2585 and A2602 in the ribosomal PTC presumably impairs the catalytic capability of
the ribosome. To the best of our knowledge, our results is the first evidence that macrolides can
dispose an vacant bacterial ribosome. It is also known that drug-regulated base flipping is a valid
mechanism for other antibiotics to act on the ribosome. For example, the aminoglycoside antibiotics
act to lock the reading head of the ribosome, A1492 and A1493 in 16S RNA, in the looped-out
orientation, leading to overwhelming misreading errors [79–81]. The bacteria may be finally killed
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by malfunctioning proteins synthesized by drug-bound ribosomes.
The base flipping transition pathways can be described by the evolution of backbone confor-
mation, which can be characterized by torsion angles of ε and α+1 [82]. As shown in Fig. 2.7,
the transition pathways of U2585 and A2602 in our simulations are consistent and described well
with a pathway calculated by umbrella sampling simulations [83], which supports the hypothesis
that the base insertion of U2585 and A2602 is a feasible conformational changes in the ribosome,
although crystallographic structure of an ERY-bound ribosome did not model U2585 and A2602 as
at the folded-in state [54]. Nevertheless, later cryo-EM modeling of a macrolide-stalled ribosome
complex [75] treated U2585 at a similar conformation as discovered in our simulations [68].
2.3.3 Coupled base flipping transitions of U2585 and A2602
In the absence of antibiotic, both U2585 and A2602 prefer the looped-out configuration, often stabi-
lized by a stacking interaction between their bases (Fig. 2.5C). Drug-induced rotation of one of the
residues would release the restriction and favor the repositioning of the other base as well. Because
simulations of drug-free and ERY-bound ribosomes start from comparable states of the PTC, in
which both residues are in looped-out conformation, their ERY-induced reorientation is compatible
with either lowering the transition barrier or changing the free energy balance between the folded-in
and looped-out states. Because of the limited sampling time, the available data are insufficient
to distinguish between these scenarios. Nevertheless, as described above (See also Fig. 2.7), the
transition pathways of U2585 and A2602 in our simulations are consistent with a general nucleotide
insertion pathway [83]. This consistency shows that the base-flipping events observed in our sim-
ulations fit the general behavior of RNA helices which favors a folded-in state [83]. Furthermore,
a structural comparison of drug-free and drug-bound ribosomal Helix 93 shows that the presense
of the drug induces a more regular packing of base stacking for the vicinity of U2585 (Fig. 2.6B),
which again would move the balance towards a folded-in state [83]. Because U2585 and A2602 can
form a stacking conformation when they both are at the looped-out state, once U2585 is folded-in
to Helix 93 A2602 is not stabilized at the looped-out state, which would move the balance towards
a folded-in state for A2602 too.
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2.3.4 Allosteric change in the PTC induced by remotely-bound
antibiotic
Presently, we can only hypothesize how the antibiotic can promote reorientation of the distal PTC
residues. Although hypothetically relocation of the antibiotic from its binding site in the ribosomal
exit tunnel to the PTC is possible, neither the published crystal structures [53, 54] nor our MD
simulations, in which binding of ERY in its tunnel site was extremely stable (Fig. 2.3A), support
this scenario. Furthermore, RNA probing experiments suggest that the drug does not move from
its conventional site when MRL peptide is placed in the tunnel (Fig. 2.3B). Therefore, we favor the
model that the NPET-bound antibiotic induces changes in the PTC allosterically. One possibility is
that a conformational relay could be initiated by rotation of the A2062 base located in the immediate
vicinity of the drug binding site in the ribosomal exit tunnel(Fig. 2.5D) and connected to the PTC
through its immediate neighbors, G2061 and C2063 [30, 33] (Fig. 2.5D). A possible alternative route
might start at U2609 on the NPET wall opposite ERY. This highly flexible nucleotide is linked to
the PTC via U1782 and U2586 (Fig. 2.5D). However, the mutations of rRNA residues in both these
pathways (e.g., A2062, U2609, U2586, U1782) have either no or only a marginal effect upon ERY-
and MRL peptide- dependent stalling [68], suggesting that either the identity of these nucleotides
is not critical for signal relay or other pathways are involved. In this regard, it should be noted
that although biochemical and computational data clearly identified the PTC as a site sensitive to
binding of antibiotic in the ribosomal exit tunnel, our MD analysis, which was performed with the
tRNA-free ribosome, cannot describe the placement of the PTC or ribosomal exit tunnel residues
in an already translating ribosome.
2.4 Modeling and computation methods
All simulations were performed using NAMD 2.9 [84] with the AMBER99SB force field [85, 86], which
includes parameters for modified nucleosides [87]. Modeling and analysis also used the program
VMD [88]. The equations of motion were integrated with a 1-fs time step and bonded interactions,
nonbonded short-range interactions, and nonbonded long-range interactions were calculated every
one, two, and four time steps, respectively. The particle mesh Ewald method [89, 90] was used
to evaluate the nonbonded long-range electrostatic interactions. All simulations were carried out
in the NpT ensemble at T = 310 K and P = 1 atm with the following protocol: water and ions
were first equilibrated for 2 ns with the remainder of the simulation system restrained, after which
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side chains of proteins and bases of nucleotides were allowed to move for another 5 ns. Finally, all
restraints were released for an equilibration of an additional 10 ns. After these first 17-ns initial
equilibrations, production simulations were performed for each system (Fig. 2.3D). All analyses were
carried out using only the production simulation data. The force-field parameters of erythromycin
were optimized in two steps. In the first step, the parameterization of partial charges of atoms
followed the standard procedure for AMBER, fitting restricted electrostatic potentials generated
from quantum mechanics calculations at the RHF/6-31G* level [91]. The calculations and fitting
were performed using Gaussian [92] and Antechamber [93], respectively. In the second step, all the
bonded terms were deduced based on analogous bonded types available in the AMBER99SB force
field [85, 86], except for the length of bonds and the values of angles involving heavy atoms, which
were taken directly from the crystal structures [53].
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Figure 2.6: (A) A typical trajectory of U2585 orientation angle and the Generalized Born [73] (GB) interaction
energy between U2585 and its molecular neighborhood, constructed by ERY U2609 A752 G1782 A2058 A2059 U2584
and U2586. The transition events are boxed. The lower GB interaction energy suggests a more stabilized structure
after the transition. (B) Structures of the looped-out and the folded-in conformations of U2585. Boxed regions of
the folded-in conformation shows strong stacking configuration of neighborhood ribosomal nucleotides, suggesting
the folded-in state of U2585 is more favorable than the looped-out state. (C) Same as (A) but for A2602. The
neighborhood of A2602 is defined by ribosomal nucleotides 2590 to 2604 except A2602. (D) Same as (C) but for
A2602. Boxed region of the looped-out conformation of A2602 shows a stacking configuration which stabilized A2602
and U2585. After U2585 transitioned to the folded-in state, A2602 subsequently transitioned to the folded-in state
too. The orientation angles are the same as Fig. 2.4. This figure uses simulation ERY1 (See Fig. 2.3).
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Figure 2.7: backbone torsion angles for U2585 and A2602 during a representative flipping transition. Inset diagram
shows the definition of ε and α+1 [82] torsion angles.
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Chapter 3
Programmable translation arrest
and antibiotic resistance
Reproduced in part with permission from P. Gupta, B. Liu, D. Klepacki, V. Gupta, K. Schulten, A. S. Mankin,
and N. Va´zquez-Laslop. The nascent polypeptide assists the ribosome in discriminating between chemically distinct
molecules. Nat. Chem. Biol., 12, 153-158, 2016. Copyright 2016 Nature Publishing Group
3.1 Introduction
The majority of antibiotic drugs target the ribosomes of bacterial cells while leaving human ribo-
somes unharmed. An example are the most widely-prescribed macrolide antibiotics, including the
oldest erythromycin (ERY) and latest telithromycin (TEL) which bind in the nascent peptide exit
tunnel (NPET) of the bacterial ribosome [20, 52–54]. Macrolide antibiotics do not bind to human
ribosomes because the structural differences present at the human ribosomal NPET [9, 94–96] as
opposed to bacterial ribosomes [53].
However, modern bacteria fight antibiotic drugs; exposing them to a specific kind of antibiotic
drug for too long will trigger the expression of drug-resistance genes, which protect the bacteria,
eventually making the drug useless. Due to historical overuse of antibiotic drugs, clinic antibiotic
drugs have experienced today serious drug-resistance problems, which is now a global crisis [44]. It
is now a central challenge to the human race that we have to fight maliciously bacteria which are
constantly evolving at the same time prevent further growth of drug-resistant bacteria.
From the bacteria’s point of view, drug-resistant gene expression in response to the changing
environment is critical for bacterial cell survival. For instance, binding of macrolide antibiotics to
the ribosome promotes translation arrest at the leader open reading frames (ORFs) ErmCL and
ErmBL, which takes the regulatory role to induce the antibiotic resistance genes ermC and ermB,
expression of which abolishes the binding of macrolide to bacterial ribosomes [97] and, therefore is
essential for bacterial cells to survive.
Ribosome-targeting macrolide antibiotics act not only as inhibitors of translation but also as
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Figure 3.1: The general scheme of antibiotic and nascent peptide-controlled induction of erm drug-resistance genes
(using the example of the ermB operon). In the absence of antibiotic, the regulatory leader ORF is continuously
translated whereas translation of ermB is attenuated due to sequestration of the Shine-Dalgarno sequence and initiator
codon (‘AUG’) in the mRNA secondary structure. At limiting concentrations of the inducer, binding of the antibiotic
to the ribosome promotes translation arrest at a specific codon of the leader regulatory ermBL ORF. The stalled
ribosome induces isomerization of the mRNA structure liberating the ribosome binding site and activating expression
of the erm gene.
activators of resistance genes [55]. Macrolides bind in the NPET approximately 10 A˚ away from
the peptidyl transferase center (PTC) [20, 52–54]. They may inhibit protein synthesis by promoting
peptidyl-tRNA dropoff during the early rounds of translation or arresting ribosome progression in a
context-specific manner [34, 57, 98, 99], or, they may change ribosomal structures at the PTC [68].
Antibiotic-dependent translation arrest has been evolutionarily cooped to enable microbial antibiotic
producers and resistant bacterial pathogens to rapidly activate expression of the resistance genes
in response to the presence of the inhibitor [64, 100, 101]. Macrolide-induced ribosome stalling at
the leader regulatory ORFs of the inducible erm genes results in the isomerization of the mRNA
secondary structure (See Fig. 3.1), which allows expression of the downstream resistance cistron
to be activated [102, 103] (See also Fig. 3.1). This mechanism takes advantage of the ability of
macrolides to bind the NPET interacting with the leader regulatory peptide, where the antibiotic
molecule interacts both with the ribosome and the nascent chain [75, 104].
The antibiotics of the macrolide family comprise a macrolactone scaffold augmented with drug-
specific side chains (Fig. 3.2). The macrolactone ring of the prototype macrolide ERY is rigged
with desosamine and cladinose sugars; however, in the drugs of the newest generation, called ke-
tolides (for example, TEL), a keto group replaces cladinose at the C3 position of the ring, and
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additional extended side chains are present. Although various macrolides have generally similar
mechanisms of action, individual erm genes can be induced only by a distinctive spectrum of an-
tibiotics [39, 75, 105, 106]. Specific macrolides serve as efficient stalling cofactors and inducers of
resistance, whereas other macrolide antibiotics fail to do so despite binding with comparable affin-
ity to the same ribosomal site [53, 107–109]. Because the sequences of the leader peptides vary
among the different erm genes [64, 65], the specificity of the antibiotic response is most likely en-
coded in the peptide structure. However, which features of the nascent peptide influence the ability
of the ribosome to discriminate between inducing and noninducing antibiotics remain unknown.
Figure 3.2: Structures of the chemically distinct cofactors of translation ar-
rest: erythromycin (ERY), telithromycin (TEL) and solithromycin (SOL). The
macrolide-scaffold, macrolactone ring, is highlighted with red circles.
In this chapter, we show
that single amino acid changes
in the leader peptide may
switch the specificity of recog-
nition of distinct macrolide
drugs, triggering gene acti-
vation in response to ERY
alone, to TEL alone or to
both antibiotics or prevent-
ing stalling altogether (See
Fig. 3.4). Thus, the riboso-
mal response to chemical sig-
nals can be modulated by minute changes in the nascent peptide, suggesting that protein sequences
could have been optimized for rendering translation sensitive to environmental cues. Furthermore,
because we can selectively modulate antibiotic-induced translation arrest, which is required for the
expression of drug-resistance genes [39, 67, 75, 97, 102–104], our work in this chapter provides
insights on fighting the global antibiotic-resistance crisis [44].
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3.2 Results
3.2.1 Molecular dynamics flexible fitting (MDFF) model of an
Ermb-stalled ribosome with ERY bound at the exit tunnel
We employed MDFF [110, 111] simulations using a 5.5 A˚ cryo-EM map of the E. coli ribosome
complex stalled by ERY with nascent polypeptide ErmBL [75] determined by our collaborator
the Wilson Lab (Gene Center Munich). As shown in Fig. 3.3A and B, our MDFF-derived model
revealed a juxtaposed positioning of the ERY drug molecule and the nascent ErmBL peptide. The
F4 residue of ErmBL forms a stable stacking interaction with ribosomal nucleotide U2609. The
R7 residue interacts with ribosomal nucleotide A2062, which has been identified as stalling sensors
in nascent protein-mediated translation arrests [40, 74]. R7 was identified as the key interaction
site for sensing the ribosome translating the ErmBL leader peptide with the presense of the ERY
macrolide [75]. Our atomic-resolution MDFF-derived model linked R7 to ribosomal A2062, a known
stalling sensor [40, 74]. The C-terminal D10 of ErmBL was aligned by ribosomal U2585. As shown
in Fig. 3.3C, F4 of ErmBL and ribosomal U2609 contribute to a local density which was also
identified as a key interaction between the ErmBL regulatory leader peptide and the ribosome [75].
Ribosomal G2251 and G2252 align the P-site tRNA as in a normal translating ribosome [23]. Our
MDFF-derived models may serve as structural basis to design mutation experiments.
3.2.2 Cofactor recognition by nascent peptide C-terminal residue
Our MDFF-derived model reveals a close interplay between the ErmBL regulatory leader peptide and
the ribosome, suggesting that ErmBL could participate in regulating translation. Our experimental
collaborator the Mankin lab performed single-point mutation screening of every amino acid on the
ErmBL chain in vitro [35]: each amino acid was mutated to the other main 19 amino acids and they
found that the identity of the C-terminal residue of the stalling peptide (Asp10 in wild-type (WT)
ErmBL), which is positioned in the PTC at some distance from the macrolide binding site, had
the most marked impact on the discrimination between the stalling cofactors, i.e. macrolide drugs
ERY or TEL. The replacement of Asp10 with glycine or even structurally similar glutamic acid
nearly abolished ketolide-mediated translation arrest at codon 10 but preserved ERY-dependent
stalling [35]. Unexpectedly, changes to proline or tyrosine had the opposite effect: the ribosome
stalled at the tenth codon in response to TEL but not ERY, as summarized in figure 3.4. All of the
other Asp10 mutations prevented sufficiently strong stalling at the tenth codon in response to any of
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Figure 3.3: Molecular dynamics flexible fitting [110, 111] was employed to determine an atomic structure of ERY-
bound E. coli ribosome translating the ermB gene. (A) The fitted ribosome model is shown with cryo-EM map [75].
The ribosomal 50S and 30S subunits are shown in cyan and yellow, respectively. Inset: atomic detail of the extensive
interactions between the ErmBL nascent peptide (green) and the ribosomal nucleotides (blue). The ERY drug co-
resides with the ErmBL peptide in the NPET and is shown in ball representation. (B) The fitted ErmBL peptide
and ERY drug are shown with the cryo-EM density map. (C) Details of the fitted ErmBL peptide and the ERY
position close to ErmBL. Ribosomal G2251 and G2252 stabilizes the P-site tRNA. For simplicity, only cryo-EM from
the ErmBL and P-site tRNA 74-76 CCA nucleotides are shown.
the antibiotics [35]. These data show that the nature of the C-terminal residue of the stalled ErmBL
nascent chain has a major role in differentiation between chemically distinct stalling cofactors bound
in the NPET. Our collaborator then tested mutations of Asp10 with in vivo ribosomal translating
systems, which gave consistent results as the above in vitro analysis [35]. Thus, by solely changing
the nature of the C-terminal residue of the ErmBL stalling peptide, it was possible to deliberately
modify the ribosomal response to specific stalling cofactors and, as a result, render gene expression
sensitive to the presence of distinct small molecules.
Nascent peptide- and small molecule-dependent programmed translation arrest relies upon in-
efficient peptide bond formation at the stalling codon [39, 67, 68, 75]. To gain insight into the
molecular mechanisms underlying peptide and antibiotic cooperation in interfering with peptidyl
transfer, we used molecular dynamics (MD) simulations to explore the behavior of representative
ErmBL mutants in the drug-bound ribosome in the pre-reaction state. The atomic model, built upon
the 4.5-A˚ resolution cryo-EM structure of the ERY- or ErmBL-stalled ribosome [75], was computa-
tionally modified to replace ERY with TEL, to remove the antibiotic, or to replace Asp10 of ErmBL
with glutamic acid or tyrosine to capture ERY- or TEL-specific stalling scenarios, respectively.
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Figure 3.4: Stalling in ERY- or TEL-bound ribosome with wild/native type or mutated ErmBL nascent polypeptide,
from biochemical assay experiments. ERY and TEL macrolide structures are shown and the distinctive cladinose ring
of ERY is highlighted by a purple circle.
Figure 3.5: The orientation of the donor and acceptor sub-
strates in the peptidyl transferase active site of the elon-
gating ribosome [23] (PDB accession number 4V5D). The
definitions of angles θx and θy characterizing the direction
of the nucleophilic attack [21, 22] are indicated. In the
crystal structure, the θx and θy angles are equal to 88o
and 122o, respectively.
The proximity of the relative geometry of
the closely spaced (≤ 6 A˚ donor and accep-
tor substrates, derived from MD sampling to
the orientation of the PTC substrates in the
elongating ribosome in a pre-reaction state [23],
was used as a measure of reactivity (Fig. 3.5
and 3.6). In the drug-free ribosome, the sub-
strates frequently approach the ‘reactive’ orien-
tation (Fig. 3.6). However, consistent with the
scenario of dual antibiotic arrest, the produc-
tive conformations are sampled less frequently
when ERY or TEL are bound to the ribo-
some carrying WT ErmBL-tRNA (Fig. 3.6). In
agreement with the experimental data [35], only
ERY skews the substrates toward unproductive
constellations with the ErmBL Glu10 mutant,
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Figure 3.6: The proximity of the structures along the MD simulation trajectories to the reactive conformation of the
donor and acceptor substrates. (Upper graphs) The θx and θy angles observed in snapshots during the simulation
sampling are indicated by color dots (green for TEL, salmon for ERY and black for the ‘no drug’ wt complex). The
point with the attack angles observed in the crystal structure 4V5D is indicated by a circled cross. The increasing
size of boxes was drawn around that point and the fraction of all the simulation snapshots fitting within the box
of a defined size were plotted in graphs shown in corresponding lower graphs. Boxes corresponding to ± 10o and
± 20o boundaries are shown for illustration. The plots are based only on the snapshots of the structures in which
the distance between the attacking α-amino group nitrogen atom of the aminoacyl-tRNA and the carbonyl carbon
atom of the ester bond of peptidyl-tRNA is ≤ 6A˚. The percentage of the total structure satisfying this criterion were:
ASP10 (no drug): 73%, ASP10(ERY): 46%, Asp10(TEL): 33%; Glu10(ERY): 0.5%; Glu10(TEL): 54%; Tyr10(ERY):
31%; Tyr10(TEL): 33%. The definitions of angles are illustrated in Fig. 3.5.
whereas TEL, but not ERY, curtails the occurrence of the productive states in the ErmBL Tyr10
complex (Fig. 3.6). Altogether, the results of MD simulations argue that misorientation of the re-
active substrates is the key contributing factor to antibiotic-induced ribosome stalling (See Fig. 3.6
and 3.9). This inference resembles the previously proposed isomerization of the ribosome into a
nonproductive state when inadequate donor substrates are bound at the PTC [112, 113].
The distance between the nucleophilic nitrogen of the amino acid in the A site and the elec-
trophilic carbonyl carbon of the P site amino acid (N-C distance) is a good measurement for peptide-
bond formation activity in a translating ribosome [33, 113]. As is shown in Fig. 3.7, both drug-bound
ribosomal systems show an increased N-C distance population with the wild-type Asp10. Consistent
with experiments [35], with Glu10 mutation, N-C distance samplings in the ERY-bound ribosomal
system apparently populated in the longer range, whereas the TEL-bound system showed a N-C
distance distribution more similar to the drug-free system. However, the N-C distance distribu-
tions in the Tyr10 mutation simulations cannot clearly distinguish ERY-bond and TEL-bound cases
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Figure 3.7: Distributions of the distances between the nucleophilic nitrogen of the amino acid in the A site and the
electrophilic carbonyl carbon of the P site amino acid (N-C distance) from MD simulations. The first peak of NC
distance distribution of “no drug” system (6 A˚) is used as the cutoff N-C distance in calculations used for generation
of Fig. 3.6.
Figure 3.8: The presence of macrolide drug in the NPET shifts the ErmBL nascent peptide away from the A site, which
contributed to misalignment of the peptide-bond formation substrates at the PTC. (A) Nascent ErmBL juxtaposed
with either ERY or TEL. In both cases the arrow shows ErmBL was pushed by the drug. (B) nucleophilic nitrogen of
the A site and ester carbon of the P site are shown in ball representations for either ERY- or TEL-bound ribosome.
Arrows show the P-site tRNA and nascent peptide was shifted into the NPET. Center structures derived from MD
simulations are used in this figure.
(Fig. 3.7 right). It is likely that in this case the orientation of the peptide-bond formation substrates
(See Fig. 3.6) play a more important role than the N-C distance for the efficiency of peptide-bond
formation.
Our MD simulations also provide detailed descriptions on the PTC structures and dynamics.
As is shown in Fig. 3.8, the presence of drug molecules obstructed the elongation path of the
ErmBL nascent peptide (Fig. 3.8A) such that the nascent peptide was pushed away from the A
site, which resulted in a shifted P-site tRNA and nascent peptide (Fig. 3.8B). Similar tRNA shifts
were observed in SecM-mediated translation arrest [32, 33] and D-amino acid-induced translation
arrest [113]. More interestingly, our MD simulations revealed unexpected molecular details that
may account for the macrolide-dependent regulation of translation arrest (Fig. 3.4). Glu10 has an
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Figure 3.9: (A) The extended glutamate side chain may allow for a direct interaction between Glu10 of the
ErmBL(Glu10) mutant peptide and the cladinose hydroxyl of ERY offering an explanation for ‘ERY only’ spe-
cific stalling. (B) Cladinose-lacking TEL does not interact with Glu10 directly, ribosomal nucleotide A2061 forms
hydrogen bonds with Glu10 instead, which facilitated alignment to maintain an optimal orientation of substrates for
peptide-bond formation (also see Fig. 3.6). (C) The increased conformational freedom of Tyr10 in the ErmBL(Tyr10)
mutant may allow the donor substrate to deviate from the productive conformation when cladinose-lacking TEL is
bound. The arrows indicate the range of conformation motion of Tyr10 side chain in the TEL complex (green) or ERY
complex (salmon); the radii of gyration calculated from the MD simulation snapshots are indicated. ERY molecule
is shown as sticks and semi-translucent surface.
extra CH2 group making it longer than the wild-type Asp10. In an ERY-bound ribosome, Glu10
can reach the hydrogen donor of the ERY cladinose ring (Fig. 3.9A), which pulled the C-terminal
ErmBL amino acid Glu10 away from the A-site Lys11. By contrast, TEL does not have the cladinose
ring structure. As a result, in a TEL-bound ribosome, Glu10 forms hydrogen bonds with ribosomal
nucleotide A2061 instead. This configuration happened to facilitate peptide-bond formation (See
Fig. 3.6) because the A- and P-site substrates were better aligned. We observed an increased
flexibility of Tyr10 in the TEL-bound ribosome, whereas Tyr10 was very stable in the ERY-bound
ribosome. We believe this finding can be also attributed to the cladinose ring of ERY, which limited
the space in which Tyr10 can swing (Fig. 3.9C).
Although MD simulations yielded a number of possible interpretations as to why specific peptides
can trigger stalling only with a certain antibiotic molecule bound in the NPET, no consistent unifying
theme has emerged. Nevertheless, two observations, which could offer fairly unorthodox potential
clues for the cofactor specificity puzzle, are worth mentioning. Analyzing the C-terminal amino
acid trajectories of the ErmBL Glu10 mutant peptide, we detected occasional direct interaction
between the γ-carboxyl of the C-terminal glutamic acid side chain with the 4’ hydroxyl of the C3
cladinose sugar of ERY (Fig. 3.6). That such an interaction, which restricts the donor substrate to
a nonproductive orientation, is impossible if the cladinose-lacking TEL binds the NPET or if Asp10,
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with its shorter side chain, is at the ErmBL C terminus could consistently explain the ‘Ery-only’
stalling response of the Glu10 mutant. MD analysis of the ErmBL Tyr10 mutant emphasized a
possible role of the conformational dynamics of the PTC substrates that could be influenced by the
cofactor: a broader rotational freedom of the Tyr10 side chain (radius of gyration 4.87 A˚ ± 1.93
A˚. (Fig. 3.9C), afforded by the lack of cladinose in the TEL structure, allows the donor substrate
to frequently wander away from the productive conformation. The movement of the Tyr10 side
chain is more constrained in the ERY complex (radius of gyration 1.10 A˚ ± 0.70 A˚ (Fig. 3.9C) thus
accounting for the TEL-specific response.
3.2.3 Cofactor C3 substituent as the main discriminatory trait
We asked which chemical features of ERY and TEL are recognized by the ribosome and nascent
peptides for differentiating between them as stalling cofactors. Although these two antibiotics differ
from each other by several structural elements, cryo-EM reconstructions [75], as well as the MD
simulation presented here, point specifically to the importance of C3 cladinose present in ERY but
lacking in TEL (See Fig. 3.4 and 3.2). Thus, to test the role of the C3 substituent in cofactor
discrimination, we compared translation arrest directed by WT ErmBL or its three representative
mutants (Glu10, Tyr10 and Val10) in response to ERY, TEL and the cladinose derivative of TEL,
RU69874 [35]. The toeprinting data showed that none of the peptides could distinguish the cladinose
version of TEL from ERY [35]. Therefore, ErmBL-assisted discrimination between the NPET-bound
antibiotics is based on the chemical nature of the macrolactone C3 chain.
3.3 Discussion
The combined results of our biochemical and computational experiments have revealed the ribosome
as a highly selective sensor of macrolide antibiotics. Its ability to recognize and discriminate between
them could be directly modulated by minor variations in the sequence of the nascent peptide. The
mutation of a single amino acid of the nascent chain could be sufficient to not only broaden or
narrow the spectrum of molecules, which can elicit the functional response of the ribosome, but also
switch the specificity of recognition from one chemical to another.
29
3.3.1 Understanding of productive cofactor recognition
Although inhibition of peptide-bond formation is a key requisite for antibiotic-specific translation
arrest [39, 67, 68, 75, 104], productive stalling leading to activation of the downstream gene requires
that two other conditions are met: (i) translation of the leader peptide must proceed unobstructed
until the ribosome reaches the site of the programmed arrest, and (ii) the stalled ribosome should
remain stably associated with mRNA to allow its isomerization into the ‘induced’ conformation
(Fig. 3.1). In fact, some of the ErmBL mutant peptides, which were unable to support efficient
formation of a stalled complex with one or both antibiotics, as measured by the absolute intensity of
the codon 10 toeprint band, were nevertheless only poorly transferred to the Lys-tRNALys acceptor,
as determined by the ratio of the ribosomes arrested at codon 10 to those able to bypass it [35].
We believe that the inability of those mutants to produce a strong stalling band in toeprinting
experiments [35] stems from the poor stability of the stalled complexes, possibly due to a rapid
dropoff in peptidyl-tRNA. Although the molecular bases of the drop-off mechanism are unknown,
the rate of peptidyl-tRNA dissociation is most likely affected by the structure of the NPET-bound
antibiotic and the nature of the C-terminal residue of the nascent peptide. Thus, cofactor-dependent
stalling peptides must have evolved to not only stop the ribosome when the cofactor is present but
also allow the ribosome to reach the site of the programmed arrest and provide sufficient stability
for the stalled complex.
To sum up, we can hypothesize the patterns of macrolide-ribosome interactions shown in Fig. 3.10.
When the drug binds to the ribosome before translation of Erm gene is in process, the drug could
change the properties of the ribosome such that the ribosome is not able to synthesize proteins prop-
erly [68]. If the drug binds to an already translating ribosome, translation arrest can be induced. The
stable and stalled ribosomal complex will trigger expression of antibiotic resistant genes (See also
Fig. 3.1); Non-stable and stalled ribosomal complexes could lead to rapid dropoff in peptidyl-tRNA.
3.3.2 Medical and evolutionary implications
Our findings have important medical implications. We showed that it is possible to control inducible
resistance to macrolide antibiotics. Our findings suggest that mutants with an altered cofactor
specificity of induction may become prevalent with the anticipated increase in the clinical use of
macrolides. Our results may also have important evolutionary implications. The marked ease with
which sensing of small molecules can be switched, adjusted and optimized by only minute changes in
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Figure 3.10: Current understanding of the interplay between macrolide ERY and translation.
the nascent peptide structure indicates that translation of many proteins could be rendered sensitive
to the chemical composition of the cell milieu. Although the known examples of small molecule-
controlled translation arrest have been described so far only for the regulatory genes, these examples,
which account for ‘extreme’ cases that require severe and prolonged translation arrest, most likely
represent only the tip of the iceberg. The amino acid sequences of many cellular proteins may
conceivably have been evolutionarily selected not only for their proper function upon completion of
their synthesis but also for enabling their translation to be finely tunable by specific small molecules
and thus, responsive to the changing environment.
3.4 Modeling and computation protocols
3.4.1 Molecular modeling
The atomic model of the ErmBL-ribosome complex was prepared by Molecular Dynamics Flexible
Fitting (MDFF) [110, 111] using the fully solvated E. coli ribosome structure [114] as the initial
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structure, which was then fitted to the cryo-EM electron density map [75]. The structures of the P-
site tRNAAspand A-site tRNALys were built according to their sequences [115], using tRNAs in the
original model [114] as a template. The corresponding matching codons in mRNA were similarly
modeled. The nascent ErmBL peptide in the ribosomal exit tunnel was modeled manually as a
fully extended chain and later refined in the MDFF simulations (described below). The MDFF
simulations were performed in a 278 A˚ × 336 A˚ × 331 A˚ explicit water box. The ribosome structure
and that with ERY were fitted first followed by stepwise fitting of the ErmBL nascent chain as
follows. Specifically, the side chains of the amino acids were removed to fit the backbone-only
peptide into the ribosomal environment in a 3-ns MDFF run. Then, starting from the C-terminal
residue, the side chains of each of the 10 amino acids of the nascent chain were fitted one at a time
in 10 consecutive 2-ns-long MDFF simulations. Finally, the resulting ribosome structure, which
included the ERY molecule and a full-atom ErmBL nascent chain, was refined with the cryo-EM
map in a 5-ns-long MDFF simulation.
The systems with the mutant ErmBL peptides were built on the basis of the MDFF model
of ERY-bound ribosome containing P-site ErmBL-tRNAAsp and A-site Lys-tRNALys. The P-site
tRNAs in the mutant systems were modeled according to their sequences [115]. For the TEL-
bound ribosome systems, ERY was replaced with TEL by docking the drug molecule according
to the reported crystallographic structure [53]. Finally, the drug-free complex was obtained by
removing the ERY compound in the model with WT ErmBL. In total, seven ribosome models were
constructed: the ribosome with WT ErmBL (with ERY or TEL or drug-free), the ERY- or TEL-
bound ribosome with the ErmBL Glu10 mutant, and the ERY- or TEL-bound ribosome with the
ErmBL Tyr10 mutant.
3.4.2 MD simulations
To achieve enough sampling at an acceptable computational cost, we constructed reduced simulation
systems of the seven above-mentioned systems by including only 23S rRNA nucleotides located
within 50 A˚ of the drug-binding site or the PTC (as defined by the position of the U2585 residue).
Atoms more than 50 A˚ away from these locations were not included in the MD simulations. Water
boxes of dimension 125 A˚ × 125 A˚ × 150 A˚ including solvating ions, were modeled using the
previously described protocol [114]. To reduce the simulation dependence on initial conditions, 10
independent MD simulations were performed for each of the seven systems. For each simulation, a
65-ns-long trajectory was calculated. The trajectory of the first 50 ns was considered sufficient for
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equilibration [68], and the last 15 ns were used for analysis. To sum up, for each model 15 ns × 10
= 150 ns sampling data was collected with 1 frame/5 ps recording rate for the subsequent analysis
using VMD [88].
All simulations, including MDFF, were performed using NAMD 2.9 [84] with the AMBER99SB
force field [85, 86], which includes parameters for modified nucleosides [87]. The equations of motion
were integrated with a 1-fs time step, and bonded, non-bonded short- and non-bonded long-range
interactions were calculated every 1 fs, 2 fs, and 4 fs, respectively. The particle mesh Ewald (PME)
method [89, 90] was used to handle the nonbonded long-range electrostatic interactions. All of the
simulations were performed in the NpT ensemble (T = 310K; P = 1 atm).
The force field parameters of the α-amino group of the A-site lysine and the ERY and TEL
compounds were optimized as described previously [68].
The center structures of each simulation were determined as follows. First, all of the RNA
residues within 20 A˚ of the drug binding site, the nascent peptide chain or the A-site amino acid
were extracted from the last 15 ns of the 10 individual simulations for each system (which amounted
to 15 ns × 10 replicas = 150 ns per system). Then, the Gromos algorithm [116] implemented in
the g cluster program from Gromacs [117] was used to determine the center structures, assuming
there is a single cluster of structures by setting the cluster root mean squared deviation (RMSD)
deviation cutoff at 10 A˚.
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Chapter 4
Molecular mechanism underlying
ribosomal discrimination of the
chirality of amino acids
Reproduced in part with permission from M. T. Englander, J. L. Avins, R. C. Fleisher, B. Liu, P. R. Effraim, J.
Wang, K. Schulten, T. S. Leyh, R. L. Gonzalez Jr., and V. W. Cornish. The ribosome can discriminate the chirality
of amino acids within its peptidyl-transferase center.Proc. Natl. Acad. Sci. USA, 112:6038-6043, 2015. Copyright
2015 The National Academy of Sciences of the USA.
4.1 Introduction
Protein synthesis occurs exclusively with achiral- or L-amino acids, thus reflecting a need for reg-
ulatory mechanisms that prevent misincorporation of D-amino acids during translation. Synthe-
sizing proteins with D-amino acids could be lethal [118, 119]. However, D-amino acid are nat-
urally abundant. The Earth’s surface temperatures can convert amino acids between L- and D-
enantimoers [120]. D-amino acid racemase enzymes are found in the brain [121]. Translation disor-
ders such as misincorporation of D-amino acids are potential underlying causes for many neurodegen-
erative diseases [122]. The ability of the ribosome to incorporate L-aminoacyl-tRNAs (L-aa-tRNAs)
with both a high degree of speed and accuracy has been the focus of decades of intense mechanistic
and structural investigations [2, 123, 124]. In contrast, the response of the ribosome to D-aa-tRNAs
has not been as well characterized. Nonetheless, a comprehensive mechanistic understanding of
how the translational machinery (TM) responds to D-aa-tRNAs is of interest for several reasons.
First, improved incorporation of D-amino acids by the TM would be useful for protein engineering
applications that seek to use the synthetic power of the ribosome to create novel polymers [125] as
well as for mechanistic applications that seek to probe protein structure and folding with unnatural
amino acids [126]. Second, there is growing evidence that ribosomes may have to contend with
D-aa-tRNAs in vivo: D-amino acids are synthesized by racemase enzymes [121] and can be found
at high concentrations in cells [127], and a growing number of aa-tRNA synthetase (aaRS) enzymes
exhibit the ability to misacylate tRNAs with D-amino acids [128]. Consistent with this possibil-
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ity, the D-aa-tRNA deacylase (DTD) enzyme is nearly universally conserved [129] and functions to
remove D-amino acids that have been misacylated onto tRNA [128, 129].
The high fidelity of protein synthesis has historically been attributed to the cumulative accuracy
with which aaRSs aminoacylate amino acids onto tRNAs [130] and with which the ribosome repeti-
tively selects and incorporates aa-tRNAs in the order dictated by the mRNA [2, 123, 124]. Once an
aa-tRNA has been incorporated into the ribosomal aa-tRNA binding (A) site, the ribosome positions
the carbonyl carbon of the ester bond linking the nascent polypeptide to the peptidyl-tRNA bound
at the ribosomal peptidyl-tRNA binding (P) site for nucleophilic attack by the α-amino group of the
amino acid moiety of the newly incorporated A-site aa-tRNA and catalyzes the peptidyl-transfer
reaction [15]. Following peptidyl transfer, the newly deacylated P-site tRNA and the newly formed
A-site peptidyl-tRNA carrying the nascent polypeptide that has been extended by one amino acid
are translocated together with the mRNA into the ribosomal tRNA exit (E) site and the P site,
respectively, preparing the ribosomal complex for the next round of the translation elongation cycle.
It is within this framework that the speed and accuracy with which the translation machinery (TM)
incorporates L-amino acids into proteins has been extensively investigated [2, 123, 124]. Although
the ability of the TM to incorporate D-amino acids into proteins has been similarly, albeit less ex-
tensively, investigated in various in vitro translation systems, these studies have found that D-amino
acids are incorporated with zero or low incorporation efficiencies [2, 123, 124].
In this chapter, we investigate the molecular mechanisms underlying the ribosome’s role in se-
lecting only L-amino acids for translation. By employing both biochemical and computational
methods, We show that the ribosome discriminates the chirality of the amino acid within its
peptidyl-transferase center (PTC). Our results demonstrate a novel mechanism through which D-
aminoacyl-tRNAs (D-aa-tRNAs) interfere with translation, provide insight into how the TM might
be engineered to use D-aa-tRNAs, and suggest additional physiological utility to a widely distributed
enzyme that clears D-aa-tRNAs from cells.
4.2 Results
4.2.1 Inhibition of peptide-bond formation by incorporation of D-amino
acids
Our model system was a translating E. coli ribosome synthesizing dipeptide fMet-L/D-Phe and
tripeptide fMet-L/D-Phe-L-Lys. Both tripeptides fMet-L-Phe-L-Lys and fMet-D-Phe-L-Lys are
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Figure 4.1: (A) Synthesis of dipeptide fMet-L-Phe and fMet-D-Phe versus time. (B) Synthesis of tripeptide fMet-
L-Phe-Lys and fMet-D-Phe-Lys versus time. (C) Structure comparison of fMet-L-Phe and fMet-D-Phe dipeptide
inside the ribosomal PTC: their sidechains adopt different orientations. (D) Elongating a dipeptide fMet-L-Phe to
a tripeptide fMet-L-Phe-Lys at the ribosomal PTC. (E) Structure of tripeptide fMet-L-Phe-L-Lys after NAMD [84]
minimization. (F) Same as (E) but for tripeptide fMet-D-Phe-L-Lys.
feasible structures in terms of stereochemical and energetic properties. When analyzed in a vacuum
environment, the two tripeptides almost have the exact total potential energy (Fig. 4.1E,F). Our
experimental collaborators the Gonzalez Lab (Columbia U.) and the Cornish Lab (Columbia U.)
engineered tRNAs that can be charged with D-amino acids [113]. Their biochemical experiments
showed that the TM can effectively, albeit slowly, incorporate a D-Phe-tRNAPhe into the A site
and produce fMet-D-Phe-tRNAPhe yield (Fig. 4.1A), which shows the ribosome can readily add a
D-amino acid to a normal nascent chain. During the next round of continuous translation of a L-Lys-
tRNALys, however, the P-site fMet-D-Phe-tRNAPhe in a subpopulation of elongating ribosomes fails
to act as a peptidyl-transfer donor and induces a robust translation arrest event (Fig. 4.1B). These
findings suggest that it is possible to efficiently incorporate D-amino acids into a nascent protein
by the TM but any further attempt to incorporate L-amino acids to the D-amino acid-containing
protein will be abolished [113].
There are two possibilities that can account for our experimental findings. First, the low yield
of D-amino acid-containing tripeptide (Fig. 4.1B) could be accounted by premature dissociation of
fMet-D-Phe-tRNAPhe. Second, the translation was stalled because the P site-bound fMet-D-Phe-
tRNAPhe is impaired as a peptidyl-transfer donor such that the peptide-bond formation is abolished.
Using radioactively-labeled tRNA, our collaborators showed that fMet-D-Phe-tRNAPhe does not
dissociate from ribosome, i.e. the elongation complex (EC) [113]. Using toeprinting assays, our
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collaborators showed that fMet-D-Phe-tRNAPhe can be successfully translocated from the A site
to the P site of ECs. As a result, it is most likely that the translation arrest that we observe in
ECs carrying P site-bound fMet-D-Phe-tRNAPhe arises from a significant defect in the ability of
the D-Phe at the C terminus of the fMet-D-Phe-tRNAPhe to participate as a donor in the peptidyl-
transferase reaction, i.e. the ribosome can discriminate D-amino acids at its catalytic center during
the process of peptide-bond formation.
Therefore, we propose a hypothesis that the peptidyl-D-aa-tRNA can stabilize the ribosome in
a conformation that cannot support peptidyl transfer. We test this hypothesis by focusing on the
ribosomal PTC, which is the most likely structure elements that account for an impaired catalysis
of peptide-bond formation by the ribosome [23, 112].
4.2.2 Disruption of ribosomal PTC by incorporation of D-amino acids
To directly test the hypothesis that the ribosome discriminates between L- and D-amino acids within
its PTC, We performed all-atom molecular dynamics (MD) simulations on ribosomes carrying either
fMet-L-Phe-tRNAPhe or fMet-D-Phe-tRNAPhe in the P site and Lys-tRNALys in the A site. Average
conformations observed in our simulations showed that the entire PTC is disrupted by the presence
of a fMet-D-Phe-tRNAPhe in the P site (Fig. 4.2A). In particular, MD simulations of the ribosome
carrying a P site-bound fMet-D-Phe-tRNAPhe revealed average conformations of A2058 to A2062
that were dramatically different from those which were observed in MD simulations of the ribosome
carrying a P site-bound fMet-L-Phe-tRNAPhe (Fig. 4.2B). Interestingly, A2058 and A2059 are the
binding site for macrolide antibiotic drugs, which are peptide-elongation inhibitors [39]and have been
implicated in the nascent polypeptide-dependent, regulatory translation arrest mechanisms of the
bacterial gene products SecM (A2058) [131] and TnaC (A2058 and A2059) [30, 31, 132]. Stabilization
of these altered conformations of A2058, A2059, and A2062 by fMet-D-Phe-tRNAPhe is allosteric, as
these nucleotides are too far away from the P site-bound dipeptidyl-tRNA to directly contact it [30].
Indeed, A2058, A2059, and A2062 are located at the entrance to the ribosomal nascent polypeptide
exit tunnel [30], where they are expected to only contact polypeptide chains that are at least four
(A2062), seven (A2059), or nine (A2058) amino acids in length [30]. Interestingly, conformational
rearrangements of these nucleotides are thought to be involved in nascent polypeptide-mediated
translation arrest mechanisms during expression of the bacterial gene products SecM (A2058) [131],
TnaC (A2058 and A2059) [132, 133], and ErmC (A2062) [39]. It is possible that A2058 to A2062
are components of a translation arrest network that can be activated in response to a variety of
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Figure 4.2: Structural comparison of the PTC core of ECs carrying either fMet-D-Phe-tRNAPhe or fMet-L-Phe-
tRNAPhe at the P site. (A) Per-residue root mean square displacement (RMSD) values between the average structures
of ECs carrying either fMet-L-Phe-tRNAPhe or fMet-D-Phe-tRNAPhe in the P site are color-coded and shown using a
trace representation of the fMet-L-Phe-tRNA Phe EC, and only structures within 15 A˚ of the P-site dipeptidyl-tRNA
are shown. (B) Nucleotides with large structural differences are shown in stick representations. PTC nucleotides are
shown in light purple (P site-bound fMet-L-Phe-tRNALys) and dark purple (P site-bound fMet-D-Phe-tRNAPhe). (C)
Changes in the C-N distances as a function of time for ECs carrying either P site-bound fMet-L-Phe-tRNAPhe (shown
in black) or fMet-D-Phe-tRNAPhe (shown in gold) and A site-bound Lys-tRNALys. C-N distances refer to the distance
between the electrophilic carbonyl carbon (C) atom of the C-terminal amino acid that is esterified to the P site-bound
peptidyl-tRNA and the nucleophilic α-amine nitrogen (N) atom of the amino acid that is esterified to the A site-bound
aa-tRNA.
regulatory situations[30, 31, 131, 132]. Our MD simulations also reveal large differences between
the average conformations of 23S rRNA nucleotides C2063, G2505, and U2506 that are observed in
the PTC of the ribosome carrying a P site-bound fMet-D-Phe-tRNAPhe and those that are observed
in the PTC of the ribosome carrying a P site-bound fMet-L-Phe-tRNAPhe (Fig. 4.2A and B). Perhaps
most interestingly, our MD simulations indicate that the electrophilic carbonyl of the P site-bound
peptidyl-D-aa-tRNA moves deeper into the exit tunnel and further away from the nucleophilic
amino moiety of the A site-bound aa-tRNA than what is observed for P site-bound peptidyl-L-
aa-tRNA (Fig. 4.2B and C), thereby suggesting a mechanism for the observed translation arrest.
A similar positioning of the P site-bound peptidyl-tRNA has been observed in cryo-EM modeling
and MD simulations of SecM-arrested ribosome [32, 33], suggesting a universal translation arrest
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Figure 4.3: The presence of a D-amino acid at the C terminus of a P site-bound peptidyl-tRNA alters the confor-
mation of the ribosome. (A) Chemical protection assays for ECs carrying either fMet-L-Phe-tRNAPheor fMet-D-
Phe-tRNAPhe. Lane 1, unmodified ECs carrying P site-bound fMet-L-Phe-tRNAPhe; lane 2, DMS-modified vacant
ribosomes (i.e., not carrying any tRNAs); lane 3, DMS-modified ECs carrying P site-bound fMet-L-Phe-tRNAPhe;
lane 4, DMS-modified ECs carrying P site-bound fMet-D-Phe-tRNAPhe. (B) Average structures of the PTCs of ECs
carrying either P site-bound fMet-L-Phe-tRNAPheand A site-bound Lys-tRNALys (shown in black) or P site-bound
fMet-D-Phe-tRNALysand A site-bound Lys-tRNALys (shown in gold) were calculated based on the last 30-ns trajec-
tories of MD simulations. PTC nucleotides are shown in light purple (P site-bound fMet-L-Phe-tRNALys) and dark
purple (P site-bound fMet-D-Phe-tRNAPhe).
mechanism. Significantly, our MD simulations show a longer distance between the α-amine of the
A-site L-aa-tRNA and the ester group of the P site-bound D-aa-tRNA versus the α-amine of the A-
site L-aa-tRNA and the ester group of the P site-bound L-aa-tRNA (Fig. 4.2C). This result suggests
that the presence of a P site-bound peptidyl-D-aa-tRNA prevents the ribosome from appropriately
positioning the reactive moieties for catalysis (Fig. 4.2).
To validate our computational results, our experimental collaborators subjected ECs carrying ei-
ther fMet-L-Phe-tRNAPhe or fMet-D-Phe-tRNAPhe in the P site to a dimethyl sulfate (DMS)-based
chemical probing assay. This assay can detect differences between the secondary structures of riboso-
mal RNA (rRNA) nucleotides in ECs carrying P site-bound peptidyl-D-aa-tRNA and those carrying
the corresponding P site-bound peptidyl-L-aa-tRNA and allowed us to assess whether such differ-
ences could be detected when comparing the two ECs. Consistent with our MD simulations results,
we found statistically significant differences in the secondary structures of 23S rRNA nucleotides
A2058, A2059, and A2062 in ECs carrying P site-bound peptidyl-D-aa-tRNA versus those carrying
the corresponding P site-bound peptidyl-L-aa-tRNA, providing strong evidence that these residues
adopt altered conformations in the presence of fMet-D-Phe-tRNAPhe relative to their conformations
in the presence of fMet-L-Phe-tRNAPhe (Fig. 4.3A).
All together, our computational and experimental findings support our hypothesis that the pres-
ence of a D-amino acid at the C terminus of a P site-bound peptidyl-tRNA stabilizes a conformation
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Figure 4.4: MD simulations showed that the incorporation of fMet-D-Phe-tRNAPhe at the P site shifted the P-site
tRNA away from the A site and more into the exit tunnel, which contributes the increased C-N distance (Fig. 4.2C). A
site-bound Lys-tRNALys is shown in gold. P site-bound fMet-L-Phe-tRNAPhe and fMet-D-Phe-tRNAPhe are shown
in black and gold, respectively. Ester group atoms at the A- and P-site are shown in ball representations (carbon:
green, oxygen: red). The black arrow shows the elongation direction, i.e. the orientation of the ribosomal exit tunnel.
of the ribosome that is different from that which is stabilized in the presence of the corresponding
L-amino acid. Notably, our biochemical assay experiment detected rRNA nucleotide A2082, which
is located 50 A˚ from the PTC in 23S rRNA helix 75, likewise adopts an altered conformation in the
presence of peptidyl fMet-D-Phe-tRNAPhe relative to its conformation in the presence of peptidyl
fMet-L-Phe-tRNAPhe [113]. The fact that A2082 is far from the PTC suggests that the presence of
a P-site fMet-D-Phe-tRNAPhe allosterically modulates not only the conformation of the PTC but
also the conformation of other, more distal regions of the 50S subunit.
4.3 Discussion
4.3.1 A generic molecular mechanism underlying translation arrest
We observed an increased distance between the α-amine of the A-site L-aa-tRNA and the ester group
of the P site-bound D-aa-tRNA versus the α-amine of the A-site L-aa-tRNA and the ester group
of the P site-bound L-aa-tRNA (Fig. 4.2C). The molecular basis underlying this finding is a shifted
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P-site tRNA (Fig. 4.4). Interestingly, the similar structural change of a shifted P-site tRNA were
reported in nascent peptide-mediated [32, 33] or antibiotic drug-triggered [35] translation arrests.
Both experimental [32] and computational [33, 35] methods derived similar conclusion. This implies
that stalling of translation due to shifted P-site tRNA might be a generic molecular mechanism
underlying how the ribosomal translation regulates stalling.
4.3.2 The selection on the chirality of amino acids determined by the
unique symmetry properties of the PTC
Figure 4.5: Overlay of MD simulation-derived orien-
tation of the P-site L-amino acid- (black) or D-amino
acid-containing (gold) dipeptides on a crystal structure
of a translating ribosome [23]. The backbone of riboso-
mal RNA helices defines a unique elongation path for
the nascent chain, which only facilitates efficient addi-
tion of L-amino acids. Ribosomal structures are shown
in blue. A-site tRNA is shown in red. An arrow shows
the orientation of the exit tunnel.
Crystallographic structures of the ribosome showed
a two-fold rotational symmetry, defined by the
backbone structures of ribosomal RNAs, near the
PTC, which is needed to accommodate two similar
chemical moieties of peptide-bond formation, i.e.
the A- and P-site tRNAs [134]. This two-fold sym-
metrical structures of the PTC defines the elonga-
tion path of nascent peptide towards the exit tunnel
(Fig. 4.5), which limits the possible orientations of
the C-terminal nascent peptide at the P site. As
is shown in Fig. 4.5 and also discussed by Yonath
and co-workers [134], incorporation of D-amino
acid may lead to serious clash with ribosomal nu-
cleotides, especially near U2585 [134] (Fig. 4.5).
We have shown that the ribosomal PTC is flexible
enough to accommodate a D-amino acid-containing
nascent peptide but the catalytic efficiency, as de-
scribed by the C-N distance (Fig. 4.2C), was signif-
icantly impaired due to the mirrored symmetry of
D-amino acid versus its L-counterpart (Fig. 4.5). The structure elements of the PTC, which defines
a specific elongation direction of the nascent peptide, is the molecular basis underlying translational
selection of L-amino acids [134].
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4.3.3 Allosteric linkage between ribosomal PTC and exit tunnel
Ribosomal nucleotides A2058 to A2062 are located at the ribosomal exit tunnel entrance (ETE).
Our results show that in addition to its ability to block peptidyl transfer, a P site-bound peptidyl-
D-aa-tRNA can allosterically modulate the conformation of the ETE. This observation raises the
intriguing possibility that peptidyl-D-aa-tRNA-mediated translation arrest at the PTC is coupled
to stabilization of particular conformations of the ETE. Such a possibility is consistent with the ob-
servation that at least one antibiotic that binds at the PTC and inhibits peptidyl transfer (i.e., chlo-
ramphenicol) also perturbs the conformations of distally located nucleotides at the ETE [135, 136]
and that resistance to such antibiotics can be conferred by mutations at the ETE [137, 138]. Indeed,
at least one previously reported interpretation of these results is that the PTC and ETE are con-
formationally coupled such that direct stabilization of a particular PTC conformation via antibiotic
binding also stabilizes a particular ETE conformation (i.e., binding of the antibiotic to the PTC
stabilizes a single PTC-ETE conformer) [136]. Stabilization of such a PTC-ETE conformer might
result in perturbation of downstream conformational transitions that inactivate the ribosome [136].
Perhaps the most compelling evidence of coupling between the PTC and the ETE, however, is pro-
vided by recent work from our antibiotics simulations [68] demonstrating that binding of macrolide
antibiotics to the ETE allosterically alters the conformation of the PTC, predisposing the ribosome
for translation arrest [68]. Thus, the results we present here contribute to mounting evidence that
the PTC and ETE are conformationally coupled and that such coupling can be used to modulate
protein synthesis.
4.3.4 Insights on bioengineering of synthetic proteins
The mechanistic insights gained from our biochemical and computational studies may help guide
future efforts to engineer the TM so as to increase the efficiency with which D-amino acids, and
possibly other unnatural amino acids, are incorporated into full-length proteins. The side-chain
dependence of the fractional subpopulation of elongating ribosomes that are not translationally ar-
rested by the presence of a P site-bound peptidyl-D-aa-tRNA suggests that steric effects involving
the side chain of the C-terminal D-amino acid prevent the ribosome from appropriately positioning
the peptidyl- and aa-tRNA substrates for catalysis and that this defect can be alleviated by iden-
tifying D-amino acid side chains that minimize these steric interactions. In addition, our results
suggest that it might be possible to engineer the ribosome so as to minimize the fractional subpop-
ulation of elongating ribosomes that are translationally arrested by the presence of a P site-bound
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peptidyl-D-aa-tRNA. For example, previous efforts to engineer the ribosome so as to increase its
ability to incorporate D-amino acids have focused on mutagenizing the PTC and 23S rRNA helix
89 (a structural element that connects the PTC to the translation factor binding site of the 50S
subunit) and have resulted in only a modest increase in the incorporation of both D-Met and D-
Phe [139]. Given that, as described in the previous paragraph, mutations to nucleotides within the
ETE have been shown to confer resistance to PTC-targeting antibiotics [137] and alleviate nascent
peptide-mediated translation arrest [39], our results raise the possibility that mutations targeting
residues situated in the ETE, rather than in the PTC or helix 89, might have a greater impact on
increasing the TM’s ability to incorporate D-aa-tRNAs. Thus, we expect that future studies aimed
at identifying and characterizing D-amino acid side chains, ribosome mutations, and/or additional
determinants that can relieve the peptidyl-D-aa-tRNA-mediated translation arrest reported here
should ultimately lead to strategies for significantly increasing the incorporation of D-amino acids
and possibly other unnatural amino acids that are currently difficult or impossible to incorporate
using the TM.
4.4 Modeling and computation methods
The starting models of the MD simulations in the current study were prepared by using empirically
determined structures of the ribosome as constraints. Specifically, we used the coordinates of the
PTC from a high- quality and high-resolution X-ray crystallographic structure that was empirically
determined by the Ramakrishnan group of a ribosome carrying Phe-tRNAPhe’s at the P site and
the ribosomal aa-tRNA binding (A) site in which the ester linkages between the phenylalanines and
the A76s of the tRNAs had been modified to amide linkages [140] as constraints for our simulations.
To prepare structural models for our simulations, however, we used Phe-tRNAPhe’s containing ester
linkages between the phenylalanines and the A76’s of the tRNAs and used only the coordinates of
backbone atoms of the Phe-tRNAPhe as constraints, ignoring the slight differences in the atom types.
Likewise, the MD simulations were performed using well-established MD algorithms to simulate the
dynamics of the ribosome. Specifically, we used parameters from the assisted model building and
energy refinement (AMBER) force field using the AMBER99SB parameter set [85, 86] to perform
the MD simulations. These MD simulation methods and the AMBER99SB force field have been
validated over many years to be reliable for describing the molecular interactions of protein-RNA
complexes, such as the ribosome [141]. The modeling of our simulation systems started with a
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fully solvated E. coli ribosome model developed by Trabuco et al. [114] that carries tRNAs at
the P and A sites and a vacant ribosomal tRNA exit (E) site. To construct the EC carrying
fMet-L-Phe-tRNAPhe at the P site and Lys-tRNALys at the A site, the P- and A-site tRNAs in
Trabuco’s ribosome model were replaced with a P-site fMet-L-Phe-tRNAPhe and an A-site Lys-
tRNALys that were modeled based on sequence information in the tRNAdb database [115]. The
backbone coordinates for the acylated P- and A-site tRNAs in our models were assigned using
the coordinates of the corresponding atoms in the previously deposited crystallographic structure
from Protein Data Bank (PDB) ID code 2WDK [23]. The EC model was then equilibrated for 30
ns by performing an equilibrium MD simulation with distance restraints between the two tRNAs
and adjacent ribosome nucleotides based on crystallographic structures from PDB ID codes 2WDK-
2WDL [23] to ensure proper interactions between the acceptor stems of the tRNAs and the ribosome
(23). To achieve enough sampling at an acceptable computational cost, we constructed a reduced
model of the EC by including only residues within 60 A˚ of the peptidyl-transferase center core, as
defined by 23S rRNA nucleotides 2585, 2451, 2062, 2063, 2505, and 2506 and the acceptor stems of
the P- and A-site tRNAs. Atoms more than 60 A˚ away from the PTC core were immobilized and
not included in the MD simulations. The water box including ions in solution for the reduced model
were modeled using a previously described protocol [114], resulting in a system size of 320,000
atoms for the actual (i.e., unconstrained) MD simulations. To obtain a model of an EC carrying
an fMet-D-Phe-tRNAPhe at the P site, we used the Visual Molecular Dynamics (VMD) [88] plugin
chirality [142] to invert the stereochemistry of the alpha carbon of the L-Phe in the model of
an EC carrying an fMet-L-Phe-tRNAPhe at the P site that was described above. During the first
5-ns equilibrium MD simulation of the EC carrying fMet-D-Phe-tRNAPhe in the P site, the fMet-
D-Phe dipeptidyl moiety quickly adopted a unique orientation that was significantly different from
that adopted by the fMet-L-Phe moiety during the first 5-ns equilibrium MD simulation of the EC
carrying an fMet-L-Phe-tRNAPhe at the P site. This unique orientation of the fMet-D-Phe moiety
was maintained through- out the subsequent simulations. To test whether the unique orientation of
the fMet-D-Phe dipeptidyl moiety might have been caused by the specific initial condition of the EC
that was used in the simulation, three independent accelerated MD (aMD) simulations [143, 144]
with dihedral potential boost were performed for the EC carrying an fMet-D-Phe-tRNAPhe.All
three aMD simulations, each of which was 30 ns long, resulted in a converged conformation of
the fMet-D-Phe dipeptidyl moiety within the PTC core that was identical to that observed in our
equilibrium MD simulations. The aMD simulations, which boost sampling of normal equilibrium
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MD simulations, were only used to test whether there were other favored con- formations of the fMet-
D-Phe dipeptidyl moiety within the PTC core; the results of the normal equilibrium MD simulation
were used for all other analyses. All simulations were performed using the Nanoscale Molecular
Dynamics version 2.9 (NAMD 2.9) program [84] with the AMBER99SB force field [85, 86], which
includes parameters for modified nucleosides [87]. Modeling and analysis also used the program
VMD [88]. The equations of motion were integrated with a 2-fs time step, and bonded interactions,
nonbonded short-range interactions, and nonbonded long-range interactions were calculated every 2
fs, 4 fs, and 6 fs, respectively. We performed two 100-ns-long equilibrium MD simulations for each
of the ECs carrying either an fMet-L-Phe-tRNAPhe or an fMet-D-Phe-tRNAPhe at the P site. MD
simulation trajectories were saved with a frame rate of 5 ps. The last 30-ns data of each simulation
trajectory were used for all analyses, for example, for generating average structures by running the
command “measure avpos” with the relevant trajectory.
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Chapter 5
Energy-dependent translational
control of the ribosome
5.1 Introduction
The ability to regulate gene expressions in response to environmental changes is essential for cell
survival, especially under acute environmental stresses [145] such as deprivation of nutrient or energy
sources. The regulation of gene expressions may exert on multiple levels [146], for example one
major mechanism is the regulation at the transcription level [147]. However, studies have shown that
protein level may not be correlated to corresponding mRNA level [41], indicating the regulation at the
transcription level may not be the mechanism underlying cellular responses to acute environmental
stress which requires a rapid adaptation for the fitness of the cell [145]. Regulation at the translation
level, i.e. translational control [148], presumably allows for an immediate and rapid response to
environmental cues because protein synthesis during translation is the last flow of gene expression
and, therefore, affect protein level directly.
Translation is carried out by the ribosome [149], which is the ubiquitous molecular machine in
living cells responsible for elongating nascent proteins by adding amino acids to a growing nascent
peptide in a process called peptide-bond transfer [5, 17, 140, 150]. Protein synthesis by the ribo-
some is a highly dynamic process [151]. First, to initialize translation the large and small ribosomal
subunits (Fig. 1.1) joined together with tRNAfMet, the initiator tRNA, and the pairing mRNA
sandwiched at the interface of the two subunits. To elongate the nascent protein, a cognate aminoa-
cylated tRNA binds to the mRNA codon at the aminoacyl-tRNA-binding (A) site (Fig. 1.1) and,
Second, the ribosome catalyzes the peptide-bond formation at the ribosomal peptidyl transferase
center (PTC), which results in a transfer of the nascent peptide chain from the tRNA bound at the
peptidyl-tRNA-binding (P) site to the A-site tRNA. Third, the ribosome translocate the mRNA
together with the paring P-site deacylated tRNA and the A-site peptidyl tRNA to the exit (E) and
the P sites, respectively. This cycle of nascent protein elongation continues until the stop codon on
the mRNA reaches the ribosome.
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Translation is one of the major energy-consuming processes in the cell [152]. Under energy-
depleted environment, the cell must be able to regulate translation until energy sources return to the
normal level to maintain long-time cellular fitness [145]. The molecular mechanism underlying stress
response to depletion of energy at the translation level is poorly understood until very recently, Boe¨l
et al. [42] characterized the functions of a protein, named as energy-dependent translational throttle
A (EttA), which may play the role of regulating translation of the ribosome under energy-depleted
conditions. Biochemical studies showed that EttA may inhibit the first peptide-bond formation in
the ribosome in ATP-depleted environment and with high concentration of ADP [42]. By contrast,
in ADP-depleted environment and with high concentration of ATP, EttA may slightly promote the
first peptide-bond formation in the ribosome [42]. EttA is also the first ABC-F protein [45] that
has been functionally characterized. And because ABC-F proteins are ubiquitous [153], a good
understanding of their structural and function relationship is of great importance.
In this chapter, we employed molecular dynamics flexible fitting (MDFF) simulations [110,
111] with a cryo-EM reconstruction of the EttA-bound ribosomal complex [43] to determine the
atomic model of the ribosome translating complex including an ATP-bound EttA. We used Replica-
Exchange Molecular Dynamics [154, 155] (REMD)-generated structures of ADP-bound EttA to
investigate the interactions between either ATP- or ADP-bound EttA and the translating ribosome.
Our computational results elucidated distinctive conformations and interaction patterns between the
translating ribosome and either an ATP- or ADP-bound EttA. Since cellular ATP/ADP level repre-
sents the energy level in cells, our results elucidated molecular mechanisms underlying an example
of energy-dependent regulation of translation by the ribosome.
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Figure 5.1: (A) Atomic model of the ribosome containing an ATP-bound EttA at the E site. This structure is obtained
by flexibly fitting atomic structures into a cryo-EM reconstruction using MDFF (Section 5.3). The ribosomal large
and small subunits are colored cyan and yellow, respectively. EttA, P-site tRNAfMet, A-site tRNAPhe and mRNA
are colored salmon, green, red and black respectively. (B) EttA binds at the E site. The A, P, and E ribosomal
sites are labeled respectively. Fitted EttA structures from three MDFF simulations using three different initial
structures of EttA obtained from Replica-Exchange Molecular Dynamics (REMD) simulations (See 5.3). The resulting
MDFF models of EttA have an average RMSD of 1.738 A˚, showing a converged fitted structure using different initial
conformations of EttA. (C) Two ATP binding pockets of fitted model showing octahedron coordinations of Mg2+ [156]
by EttA protein sidechains and water molecules.
5.2 Results and Discussion
5.2.1 Atomic models of ribosome-EttA complexes derived by MDFF
EttA in physiological conditions is a single-chain monomeric protein that features two stable nucleotide-
binding cores, a helix hairpin arm, which may interact with the ribosomal L1 stalk (named L1-stalk
arm), and an α-helical arm that may interact with the P-site tRNA, called the P site interaction
motif (PtIM) [42]. The crystallographic structure of EttA shows that the protein has two asymmet-
ric nucleotide binding pockets [42]. Although it is possible that the two binding pockets can bind
different nucleotides, in this paper we focus only on two scenarios that represent the two extreme
cellular environments of either energy-rich, featuring excessive amount of ATP but no ADP, or
energy-depleted, featuring excessive amount of ADP but no ATP. Under such extreme cases, EttA
was shown to either bind two ATP or two ADP in the nucleotide binding pockets [42, 43]. We
note that those two cases are the only ones in which the function of EttA were characterized by
biochemical experiments [42].
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Figure 5.2: The Per-residue root mean square fluctuations
(RMSFs) for ATP- and ADP-bound EttA in water ob-
tained from 300-ns equilibrium MD simulations. Residues
at the L1 stalk arm (colored deep blue in structure), which
may interact with the ribosomal L1Stalk, and at the PtIM
arm (colored brown in the structure), which may interact
with the P-site tRNA, are more flexible than the core region
(colored grey in structure).
We first performed 300-ns equilibrium sim-
ulations of either ATP- or ADP-bound EttA
solvated in water. The L1-stalk arm and the
PtIM arm are extremely flexible, whereas the
nucleotide-binding cores are relatively stable
(Fig. 5.2). Furthermore, ADP-bound EttA has
more flexible arms, compared to that of ATP-
bound EttA, as is demonstrated by the Per-
residue root mean square fluctuations (RMSFs)
plots in Fig. 5.2. This observation suggested
that the type of nucleotide bound to EttA,
namely either ATP or ADP, would affect the
conformations of EttA’s two flexible arms which
presumably may interact with the translating
ribosome. To gain a better insight of possible
conformational changes that can be induced by
replacing ATP with ADP molecules in EttA, an
enhanced sampling approach, replica-exchange molecular dynamics (REMD) simulations [154, 155]
were performed with either ATP- or ADP-bound EttA solvated in a water box (See Section 5.3),
Our REMD simulations generated distinctive arm conformations for ADP-bound EttA as compared
to that of ATP-bound EttA (Section 5.3). We then used three representative conformations of ATP-
bound EttA, generated by REMD simulations and selected by clustering analysis (Section 5.3) as
the initial conformations of EttA to model a translating ribosome-EttA complex. We performed
molecular dynamics flexible fitting (MDFF) simulations [110, 111] with an 7.0 A˚ resolution cryo-EM
map [43], encompassing an E. coli ribosome, an A-site tRNAPhe, a P-site tRNAfMet and an ATP-
bound EttA, to obtain atomic models of the ribosomal-EttA complex (ribo-EttA·ATP) (Fig. 5.1A).
The representative conformations of ADP-bound EttA, generated by REMD simulations, were used
to replace the ATP-bound EttA of the MDFF-derived ribo-EttA·ATP models to obtain the initial
structure of the ribosome-EttA complex with an ADP-bound EttA at the E site (ribo-EttA·ADP).
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5.2.2 tRNA misalignment induced by ADP-bound EttA
The ribosome elongates the nascent peptide by catalyzing peptide-bond formation at its catalytic
center, namely the peptidyl transferase center (PTC). This process relies on a precision alignment
of the A-site and P-site reaction substrates [14, 16], namely the A-site aminoacyl-tRNA and the
P-site peptidyl-tRNA. We performed atomic-level MD simulations with the ribo-EttA·ATP and the
ribo-EttA·ADP systems. We found that the presence of an ADP-bound EttA at the ribosomal E site
shifted the elbow region of the P-site tRNAfMet, namely the dihydrouridine loop (D-loop), towards
the A-site tRNAPhe, compared to that in the ribo-EttA·ADP simulations. As the tRNA may rotates
around its anticodon stem [157, 158] (Fig. 5.3B), this shift induced a movement at the acceptor stem
of the P-site tRNAfMet (Fig. 5.3B), as demonstrated by the distribution of the distances between
the nucleophilic α-amine nitrogen (N) atom of the amino acid that is to be esterified to the A-site
aminoacyl-tRNA and the electrophilic carbonyl carbon (C) atom of the C-terminal amino acid that
is esterified to the P-site peptidyl-tRNA (N-C distance). (Fig. 5.3C and D).
The spatial arrangement of structural elements at the ribosomal PTC determines the efficiency
of peptide-bond formation [19]. The peptide-bond formation reaction favors a certain orientation
for the α-amine nitrogen (N) atom at the A site relative to the electrophilic carbonyl carbon (C)
atom at the P site [15, 21, 22]. Deviation from the optimal orientation would reduce the efficiency
of peptide-bond formation [21, 22]. Nevertheless, the N-C distance is the most important measure-
ment for peptide-bond formation reactivity because, as demonstrated by the induced-fit mechanism
underlying the ribosomal catalysis of peptide-bond formation [15], the ribosomal PTC nucleotides
may spontaneously adjust P- and A-site substrates to reach a proper alignment when the two sub-
strates come close within a certain range [15]. Therefore, our finding suggested that the increased
N-C distance due to the misalignment of tRNAs, which is regulated by EttA at the E site, may
account for the regulation of peptide-bond formation, presumably with the ADP-bound EttA inside
the ribosome [42].
5.2.3 Structural properties at the interface of EttA PtIM arm and its
ribosomal environment
MD simulations revealed different conformations (Fig. 5.4) of either ATP- or ADP-bound EttA
inside the ribosome and distinctive interaction patterns at the ribosome-EttA interface. The PtIM
arm of ATP-bound EttA adopted a configuration of “three-point contact” with the ribosome and the
P-site tRNAfMet (Fig. 5.4A(a-c)). Those contacts were established by charged residues on the EttA
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Figure 5.3: Molecular Dynamics (MD) simulations revealed that ADP-bound EttA changes the positioning of the
P-site initiator tRNA, tRNAfMet, to regulate protein synthesis in the ribosome. (A) Positioning of EttA relative to
P- and A-site tRNAs. The N-C distance refers to the distance between the nucleophilic α-amine nitrogen (N) atom
of the amino acid that is to be esterified to the A-site aminoacyl-tRNA and the electrophilic carbonyl carbon (C)
atom of the C-terminal amino acid that is esterified to the P-site peptidyl-tRNA. The tRNA angle refers to the angle
formed between the acceptor stems of the P- and A-site tRNAs. The arrows show the principal axes of inertia, used
to calculate the angle values, corresponding to the smallest moments of inertia for each of the acceptor stems of P-
and A-site tRNA.(B) Structure of tRNAs inside the ribosome. The ADP-bound EttA induces a rotation motion of
the P-site tRNA such that the N-C distance the in ADP-bound system is longer than that in the system with an
ADP-bound EttA. The salmon and ice blue structures shown are center structures indicated by cross lines in (C)
from ribo-EttA·ATP simulations and in (D) from ribo-EttA·ADP simulations, respectively. The structure of A-site
tRNA shown here is the center structure extracted from the ribo-EttA·ATP simulations. Structures are aligned by
A-site tRNA. (C) The 2D plots of N-C distance and tRNA angle (defined in A) from the ribo-EttA·ATP simulations.
Data point corresponding to the center structure resulted from clustering analysis (See 5.3) is labeled by cross lines.
(D) Same as (C) but from the ribo-EttA·ADP simulations.
PtIM arm, especially arginine sidechains. The first contact point is at ribosomal Helix 69 of the large
subunit, where the positively-charged Arg266 sidechain inserted into the negatively-charged groove
of ribosomal helix, or formed hydrogen bonds with G1928 of Helix 69 (Fig. 5.4A(a)). The second
contact point is at the P-site tRNAfMet acceptor stem, where Arg277 and Lys281 on the hairpin
loop of the PtIM arm formed hydrogen bonds with the backbone phosphate groups of the P-site
tRNAfMet or interact with nucleotides through the tRNA minor groove (Fig. 5.4A(b)). The last
contact point is at the unique D-loop bulge present only on initiator tRNA [115], namely C17 and
U17a (‘17a’ means an additional nucleotide between the 17th and 18th nucleotides.), where Arg293
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stabilized C17 via cation-pi interactions [159] and Lys286 formed hydrogen bonds with backbone
phosphate groups of the D-loop bulge (Fig. 5.4A(c)). By contrast, ADP-bound EttA showed “one-
point contact” in our simulations. Due to the distinctive placement of the PtIM arm as opposed
to that in the ribo-EttA·ATP simulations, the PtIM arm of ADP-bound EttA only interacted with
the D-loop of the P-site tRNAfMet. Notably, Arg277 on the ADP-bound EttA interacted with the
D-loop (Fig. 5.4A(d)), whereas Arg277 on the ATP-bound EttA interacted with the acceptor stem
(Fig. 5.4A(b)). Arg265 and Tyr302 also participated in the stable interplay with the D-loop. Even
if ADP-bound EttA had contact only at the D-loop of P-site tRNAfMet, this interaction pattern is
stable. The number of hydrogen bonds between EttA and its ribosomal surroundings were counted
in our simulations. Both ribo-EttA·ATP and ribo-EttA·ADP simulations had maintained multiple
hydrogen bonds at the EttA-ribosome interface. The ribo-EttA·ATP system had more hydrogen-
bond counts (Fig. 5.4B) than that of the ribo-EttA·ADP system, presumably due to the observation
that ATP-bound EttA had two more points of contact with its surroundings than ADP-bound EttA
did in the simulations (Fig. 5.4B).
EttA inside the ribosome clearly affected the dynamics of the P-site tRNAfMet (Fig. 5.4C). Com-
pared to the effect of ATP-bound EttA, ADP-bound EttA stabilizes the tRNAfMet as is shown by
a lowered overall flexibility of tRNAfMet. The nucleotide flexibility of the acceptor stem and the
D-loop bulge regions of tRNAfMet showed dramatic changes if we compare the ribo-EttA·ATP sim-
ulations to the ribo-EttA·ADP simulations. Those regions carries the signature nucleotide features
of the initiator tRNA, i.e. tRNAfMet, whereas elongator tRNAs, such as tRNAPhe, have very dif-
ferent nucleotide configurations at those regions [4]. Note that the structural elements underlying
the interplay between EttA and its ribosomal surroundings are also located at the acceptor stem
and the D-loop bulge regions of tRNAfMet (Fig. 5.4). Our finding may suggest that EttA recognizes
initiator tRNA at the acceptor stem and the D-loop bulge, which may at least partially account
for the biochemical observation that EttA only regulates the first peptide-bond formation when the
initiator tRNA, i.e. tRNAfMet, binds at the ribosomal P site but have little effect on elongator
tRNAs after the ribosome has cleared the first peptide-bond formation [42]. More interestingly, the
38th nucleotide of tRNAfMet which is located at the anticodon stem (Fig. 5.4), the pivot point of
tRNA rotation motions (Fig. 5.3), lost flexibility with an ADP-bound EttA interacting with the
tRNA, whereas with an ATP-bound EttA this nucleotide is much flexible. This finding suggests
that the rotation motion of tRNAfMet can be suppressed by an ADP-bound EttA. Indeed, the range
of tRNA rotation angle covered by tRNAfMet in ribo-EttA·ADP simulations is about 4o narrower
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Figure 5.4: Interactions between EttA PtIM arm and the ribosome and P-site tRNAfMet have distinctive patterns
between ATP- and ADP-bound systems. (A) Middle: Center structures of ATP- (salmon) and ADP-bound (ice blue)
EttA PtIM arms resulting from MD simulations. The surrounding environment of ATP-bound EttA PtIM arms are
shown in surface representations. Enlarged windows: MD simulation snapshots. The ATP-bound system have three
points of interaction between the EttA PtIM arm and the ribosome-tRNA complex at (a) ribosomal Helix 69, (b)
P-site tRNAfMet acceptor stem and (c) D-loop bulge. The ADP-bound system have one point interaction between
the EttA PtIM arm and the P-site tRNA D-loop bulge, shown in (d). (B) Number of hydrogen bonds between EttA
and its surrounding structures are counted in ATP- and ADP-bound systems. (C) Per-residue RMSFs of the P-site
tRNAfMet in ATP- and ADP-bound systems, obtained from MD simulations (See 5.3).
than that in ribo-EttA·ATP simulations (Fig. 5.3C,D).
5.2.4 Conformational changes at the nucleotide binding pocket
To explore why ATP- and ADP-bound EttA behaved differently inside the ribosome, we extracted
the center structures of EttA from ribo-EttA·ATP and ribo-EttA·ADP simulation trajectories
using a clustering algorithm [116] with a cutoff of 15 A˚ (Fig. 5.5). Due to lacking of the γ-
phosphate group on ADP, the binding pocket of ADP near the PtIM arm opened the flanking
loop to the nucleotide. Loop side-chain Asn41 reached to the PtIM arm helix segment 294 to
310 such that the PtIM arm segment did not reach to the P-site tRNAfMet. By contrast, the
binding pocket of the ATP-bound EttA was intact. The flanking loop residue Asn41 binds to the
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Figure 5.5: Top: the nucleotide binding pocket near
the EttA PtIM arm maintained its Mg2+ coordina-
tion configuration during MD simulations of the ribo-
EttA·ATP system. The helix segment of the PtIM is
away from the binding pocket. Bottom: Same as Top
but for the ribo-EttA·ADP system. The ADP-binding
site loop represented by Asn41 favors an open confor-
mation and interacts with the helix segment of the EttA
PtIM arm. The P-site tRNAfMet is colored in green
and rendered by a surface representation.
γ-phosphate group on ATP most of the simula-
tion time. The conformational change from ATP-
bound state to ADP-bound state may be induced
by nucleotide hydrolysis. Our MD simulations
revealed equilibrium conformations for ATP- and
ADP-bound states respectively. While the simu-
lation cannot address ATP hydrolysis, the average
structures of ATP- and ADP-bound EttA inside
ribosome, as represented by center structures ex-
tracted from simulations, can provide a possibility
that the equilibrium state of the PtIM arm with ei-
ther ATP or ADP bound may assume different con-
formations. And the flanking loop residue Asn41
may provide stabilization for either ATP- or ADP-
bound EttA to populate in their favorable states.
However, our simulation trajectories do not show
much difference on the other nucleotide binding
site, which is near the L1-stalk arm, with an RMSD
about 2 A˚ calculated using the center structures of
EttA residues within 4 A˚ of the nucleotides. The two nucleotide binding sites of EttA have dif-
ferent surrounding environments [42], the binding site near the L1-stalk arm has a tight enclosure,
compared to the binding site near the PtIM, the nucleotide in this binding pocket is less likely
to be exchanged [42]. The stable configuration observed from MD simulation is consistent with
crystallographic structure but our simulations cannot address ATP hydrolysis. It is possible that
a conformational change can be driven by ATP hydrolysis but both ATP- and ADP-bound states
favor a similar local conformation of the binding pocket.
5.2.5 Conclusion
MD simulations using MDFF-derived atomic models of the EttA-ribosome complex with either an
ATP- or ADP-bound EttA demonstrated that ADP-bound EttA may inhibit peptide-bond formation
at the ribosomal PTC by interacting with the P-site tRNAfMet. Structural elements that may
account for the interactions were identified at the interface among EttA’s PtIM arm, the ribosomal
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Helix 69 and the P-site tRNAfMet. The arg277 at the PtIM arm is of great importance, which may
interface EttA and the P-site tRNAfMet. At the ATP-state, arg277 interacted with the acceptor stem
of P-site tRNAfMet, whereas at the ADP-state, arg277 interacted with D-loop of P-site tRNAfMet.
A large conformational re-arrangement was observed at one of the nucleotide binding site on the
EttA after an ATP molecule was replaced by an ADP molecule. The local conformational re-
arrangement at the nucleotide binding site may likely be the result of the driving force that induced
the conformational change at the EttA’s PtIM arm. Though our MD simulations cannot reveal the
effect of ATP hydrolysis, which may be an important process to drive conformational changes or the
release of EttA [42], our results demonstrated that there may be conformational differences between
equilibrium states of ATP- and ADP-bound EttA inside the ribosome, which can be stabilized by
the structural elements at the interface of EttA and its immediate ribosomal surroundings. The
Arginine-rich PtIM arm may be of functional importance. The ribosome as well as tRNAs are
negatively charged, especially at the RNA backbone atoms. Positively charged arginine sidechains
prefer to interact with the RNA backbone, which was showed by MD simulations as the important
interfacing media for regulating ribosomal translation depending on whether ATP- or ADP-bound
EttA is present in the ribosome. Biochemical mutation experiments would be used to verify our
findings. For example, our MD simulation results implies that changing arg277 to a charge-neutral
amino acid would disrupt EttA’s function for regulating translation; the effects betweeen ATP- and
ADP-state could not be distinguishable because the stabilizing effect of arg277 at either state would
be lost. Since the relative levels of ATP and ADP molecules in living cells represent energy levels,
our MDFF models and MD simulations revealed molecular mechanisms underlying translational
control in response to energy-depleted stresses.
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5.3 Methods
5.3.1 Simulations of ATP- and ADP-bound EttA structures in water
We extracted atomic coordinates of the EttA from PDB 3J5S, which is an atomic model of the
EttA-bound ribosome complex solved previously by in vacuo MDFF simulations [43], as our start-
ing point to model the EttA structure in water. The coordinates of EttA’s nucleotide-binding
sites were modeled according to a canonical ATP-binding site structure solved by crystallogra-
phy [160] (PDB 3QF7). Coordinates from the nucleotide binding site of 3QF7 were copied to
corresponding atoms of EttA. This ATP-bound EttA protein was then solvated in a water box of
dimension 102 A˚ × 116 A˚ × 94 A˚ using VMD [88]. The resulting simulation system represents
an ATP-bound EttA in water. Number of atoms is 107,000. To obtain a simulation system of
Figure 5.6: REMD-generated represen-
tative structures of EttA.
ADP-bound EttA in water, the γ-phosphate groups of the two
ATP molecules in the system of ATP-bound EttA in water were
deleted computationally. For each system, 5000-step minimiza-
tion were performed then 350-ns NpT (T = 310K; P = 1 atm)
equilibrium simulation where performed. The equations of mo-
tion were integrated with a 1-fs time step, and bonded, non-
bonded short- and non-bonded long-range interactions were cal-
culated every 1 fs, 2 fs, and 4 fs, respectively. The particle mesh
Ewald (PME) method [89, 90] was used to handle the nonbonded
long-range electrostatic interactions. Only the last 300-ns trajec-
tories of either ATP- or ADP-bound EttA in water simulations
were used for analysis; the first 50-ns trajectories are considered as equilibration.
5.3.2 Replica-exchange molecular dynamics (REMD) simulations
We performed Replica-Exchange Molecular Dynamics (REMD) simulations [154, 155] of either an
ATP- or ADP-bound EttA solvated in water. Using randomly-chosen frames from the equilibrium
simulations of either ATP- or ADP-bound EttA in water as the starting structures, 70 replicas
with temperatures in the range 310 to 410 K with an temperature distribution calculated using an
online REMD replica predictor [161] to obtain an expected exchange rate of about 0.15 in the desired
temperature range. All replica simulations were conducted at constant volume. In total, about 2.3µs
sampling of REMD simulations were collected for each of the ATP- or ADP-bound EttA in water.
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Figure 5.7: Root means squared deviation (RMSD) trajectories showed that the three MDFF simulations of the
ATP-bound EttA-ribosome complex have converged.
The representative structures of REMD-generated trajectories were determined by performing a
clustering algorithm [116] by setting the cluster root mean squared deviation (RMSD) cutoff at 3
A˚ and choosing the center structures of the top ten clusters. Then, based on the percentage of α-
helical contents at the L1-stalk arm and the PtIM arm, top 3 structures were chosen resulting three
representative structures for each system (Fig. 5.6). The three chosen structures roughly represent
50% of the REMD trajectories.
5.3.3 MDFF simulations
We used three representative structures of ATP-bound EttA in water, generated by REMD sampling
(See above), as starting conformations for ATP-bound EttA inside the ribosome. We used the fully
solvated E. coli ribosome structure [114], modeled by Trabuco et al. (Trabuco ribosome), which
comprises an A-site tRNAPhe and a P-site tRNAfMet, as the starting point to prepare our explicit-
solvent MDFF simulations. The Trabuco ribosome was rigid-body-docked into the 7.0 A˚ resolution
cryo-EM map [43] of the ribosome-EttA complex. First, a 3-ns MDFF simulation was performed
to fit the Trabuco ribosome to density. Second, atomic coordinates of the three representative
structures of ATP-bound EttA in water were extracted and rigid-body-docked into the Trabuco
ribosome using backbone atoms of EttA from PDB 3J5S as alignment. Clashing water and ion
atoms which were within 2.4 A˚ to the docked EttA structures were computational removed. Finally,
three 3.8-ns-long MDFF simulations, each using a representative EttA structure generated from
REMD samplings (See above), were performed to determine the final atomic models of the EttA-
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ribosome complex (Fig. 5.1). Due to the constraint from the cryo-EM map [43], the three resulting
models are essentially a converged structure with an average RMSD of 1.738 A˚.
5.3.4 MD simulations of ATP- and ADP-bound EttA in the ribosome
Biophysical experiments have shown that the EttA-bound ribosome reduces the overall system dy-
namics and the ribosomal complex is locked into a hibernating conformation [43], which suggests
that large conformational changes of the ribosome is unlikely to happen with EttA bound and local
structural arrangement involving the vicinities of EttA may be important for the function of EttA
inside the ribosome. Therefore, for each three MDFF-derived ATP-bound EttA-ribosome models,
we excluded structures far away from EttA and constructed a reduced model of the EttA-bound ri-
bosome by including only residues within 20 A˚ of ribosomal L1 stalk, EttA, P- and A-site tRNAs as
well as the peptidyl-transferase center core, defined as 23S rRNA nucleotides 2585 and the acceptor
stems of the P- and A-site tRNAs. The boundary constraint of the reduced systems and the water
box including ions in solution for the reduced model were modeled using a previously described proto-
col [114]. The resulting systems have about 790,000 atoms for the actual MD simulations (Fig. 5.8).
Figure 5.8: Simulation subsystem representing
a ribosome translating complex with an A-site
tRNAPhe (red), a P-site tRNAfMet (green) and
EttA (salmon). The actual simulation system
is shown in color, with the rest of the ribosome
structure shown in light gray for reference.
To obtain reduced simulation systems for ADP-
bound EttA inside the ribosome, the ADP-bound EttA
representative structures generated by REMD simula-
tions were used to replace the ATP-bound EttA. Local
clashes were fixed manually in VMD [88]. The energy
minimization and equilibration of the reduced systems
were run using a previously described protocol [114]. For
each simulation system, a 500-ns trajectory was calcu-
lated. the trajectory of the first 100 ns was considered
sufficient for equilibration [68], and the last 400 ns were
used for analysis. To sum up, for each simulation of the
reduced system, 3 (starting structures) × 400 ns = 1.2µs
sampling data was collected with 1 frame/20 ps record-
ing rate for the subsequent analysis using VMD [88].
All simulations, including MDFF, were performed using NAMD 2.9 [84] with the AMBER99SB
force field [85, 86], which includes parameters for modified nucleosides [87]. For MDFF simulations,
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The equations of motion were integrated with a 1-fs time step, and bonded, non-bonded short- and
non-bonded long-range interactions were calculated every 1 fs, 2 fs, and 4 fs, respectively. For MD
simulations of the reduced simulation systems for ATP- and ADP-bound EttA inside the ribosome,
The equations of motion were integrated with a 2-fs time step, and bonded, non-bonded short- and
non-bonded long-range interactions were calculated every 2 fs, 2 fs, and 6 fs, respectively.
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Chapter 6
Conclusions and outlook
Ribosomal translation is the last flow of gene expression in cells, which produces functional proteins
that are the real workhorse of most cellular processes. Translation is the most important cellular
process and is highly controlled, in regard to regulate gene expression, avoid errors or adapt to
acute environmental changes. Ribosomal translation involves a series of highly dynamic processes,
most of which are still poorly understood due to the lack of structural data and tools to realistically
describe the highly dynamics processes. Recent development in electron microscopy with compu-
tational innovations such as molecular dynamics flexible fitting (MDFF) method allows significant
new insights into structures of the ribosome and mechanisms of translational control. Large-scale
molecular dynamics (MD) simulations, allowed by the advancement of supercomputing hardware
and software, have delivered unprecedented details of the ribosomal translation. This thesis is a
result of employing state of the art computational techniques on the study of translational control
by the ribosome.
In Chapter 2, MD simulations of the full ribosome system at the sub-microsecond timescale un-
veiled a previously unknown effect of antibiotics. We showed that the clinically-important macrolide
antibiotic may predispose the ribosome by changing its structures, whereas previously people be-
lieved macrolide antibiotic kills bacteria by clogging the bacterial ribosomal exit tunnel to prevent
nascent protein elongation. Our results opened up a new view on possible drug actions and rec-
onciled current evidences on antibiotic action better. Yet, there are still challenges a head of us.
While we confirmed that antibiotics targeting the ribosome, such as macrolide drugs, may predis-
pose bacterial translation with a vacant bacterial ribosome. Or, it may trigger the expression of
drug-resistant genes in a ribosome translating regulatory peptide, such as ErmB. Or, it may stall
translation when the ribosome is synthesizing certain sequence of nascent peptide, resulting in re-
cycling of the ribosomal complex. However, it is unknown whether binding of macrolide can still
change the ribosome structure after the translation has synthesized a long nascent peptide. Ribo-
somal exit tunnel can certainly accommodate both macrolide and a longer nascent peptide as is
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shown by our MDFF-derived model in Chapter 2 with a regulatory stalling peptide. However, it is
a challenge to know whether macrolide would have any effect to the ribosomal complex coexisting
with a non-regulatory, non-stalling peptide which is long enough to pass the drug binding site. It
is likely sequence-specific regarding the nascent protein. But future work is needed to investigate
the drug effect on non-regulatory, non-stalling nascent peptide to complete the understanding of
antibiotic action on ribosomal translation.
In Chapter 3, MDFF and MD simulations revealed a promising engineering solution to fight
antibiotic resistance problem. Together with biochemical experiments, we found that specific pattern
of the C-terminal sequence of the regulatory leader peptide can modulate translation arrest, which is
a prerequisite for the expression of macrolide-resistance genes. We showed that the nascent peptide
may interact with unique structures on drug molecules, which may abolish or trigger translation
arrest, depending on the identity of the C-terminal amino acid on the nascent peptide. Namely,
the regulatory leader peptide for drug-resistance genes may recognize the drug by interacting with
structural features of the drug molecule. We identified the C3 cladinose ring of erythromycin is one
recognition structure. It is now a challenge that, based on our findings, design of next-generation
antibiotic drug with certain features that may only stall synthesis of proteins of non-resistance genes
but relieve translation arrest when the ribosome is translating regulatory leader peptide of resistance
genes. Furthermore, future work is needed to address the molecular mechanisms underlying the
linkage between translation arrest and expression of drug-resistance genes, which may open up
another opportunity to fight the drug-resistance problem.
In Chapter 4, we demonstrated that the ribosome may select amino acids by their chirality prop-
erties. This new finding breaks the conventional assumption of the silent role of nascent peptide in
control of translation fidelity. MD simulation revealed that due to different orientations of peptide
containing L- or D-amino acids, the ribosomal peptidyl-transferase center may undergo structural
re-arrangement to select only L-amino acid for elongation of nascent peptide. It is now a challenge
to engineer unnatural amino acid to be synthesized by the ribosome. Our findings with atomic
resolution may be used to guide such effort. Furthermore, we demonstrated the molecular mecha-
nism underlying ribosomal discrimination of the chirality of amino acids using a short peptide, i.e.
dipeptide or tripeptide, which may reorient its elongation direction to be rejected by the ribosome
(D-amino acid) or to be accepted by the ribosome (L-amino acid). It is still unknown whether the
ribosome would discriminate amino acids by their chirality if the P-site nascent peptide is a much
long one such that reorientation of the peptide is much harder to achieve.
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In Chapter 5, computational investigations revealed the molecular basis underlying nucleotide-
dependent translation control. We found that under energy-depleted environment, represented by
ADP-bound EttA, the first peptide-bond formation may be inhibited by EttA, whereas under energy-
rich environment, represented by ATP-bound EttA, the requirement for efficient peptide-bond for-
mation inside the ribosome can be met. However, it is still unknown what is the effect of ATP
hydrolysis, which presumably may drive conformational changes that is relevant for EttA’s func-
tion. Due to the limitation of our MD simulation technique, we were unable to address this issue.
It could be the case that ATP-hydrolysis may provide the energy for the release of EttA from the
ribosome such that the elongation cycle can carry on.
To sum up, we have showed great discoveries made possible by applying modeling and simulation
techniques with complex biomolecular systems. There are still a lot of interesting questions to be
answered and we are sure computations may be proven as one of the most important techniques for
the investigation of complex biomolecular processes, such as translational control by the ribosome.
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Appendix A
Molecular dynamics simulations
and flexible fitting modeling
MD simulations
Biomolecules are modeled as polymer particles in MD simulations, which computes the time-resolved
trajectories for all interacting particles of the biomolecular system by solving the Newton’s equations
of motion for the system (Eq. A.1). Physical properties of the biomolecular system can be derived by
analyzing the trajectories, which essentially record the behavior of the biomolecules in the duration
of the MD simulations.
mi
d2Ri
dt2
= −∇RiUMD(R1, R2, . . .) = −∇RiUMD(
−→
R ) (A.1)
Here mi is the mass of particle i, Ri is its position, and UMD is the total potential energy that is
a function of all particle positions and, thereby, couples the motion of particles. In the so-called
all-atom MD simulations, each atom is modeled as a single particle which has a set of parameters,
such as charge and radius, to describe the intrinsic properties of the atom in simulations.
All-atom MD simulations employs force fields [162] to describe the total potential energy (UMD)
of atomic systems as a function of spatial arrangement of all atoms (Ri). The force acting on every
atom can be determined by the total potential energy function with respect to the rest of the system.
A common form of the function is given in Eq. A.2:
UMD(
−→
R ) =
∑
bond
kbondi (ri − r0)2 +
∑
angles
kanglei (θi − θ0)2 +
∑
dihedrals
kdihedrali [1 + cos(niφi + δi)]
+
∑
i
∑
j>i
4εij [(
σij
rij
)12 − (σij
rij
)6] +
∑
i
∑
j>i
qiqj
4piε0rij
(A.2)
Here the first three terms accounts for bonded interactions, as illustrated in Fig. A.1. In Eq. A.2,
the bond term accounts for covalent bonds, representing the stretching motion of each pair of bonded
atoms; the angle term accounts for angles between each pair of covalent bonds that share the same
atom, representing the bending motion of each pair of connected bonds; the dihedral term accounts
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Figure A.1: Bonded potential energy terms in MD force fields illustrated with a peptide bond.
for the spatial relationship of a group of four atoms separated by exactly three covalent bonds
with the central bond subject to a torsion angle φ. The last two terms accounts for non-bonded
interactions including the van der Waal’s potential as the fourth term and the pairwise electrostatic
potential as the last term. The force fields parameters are predetermined to account for every type
of interactions among atoms in MD simulations [162].
All simulations are performed using NAMD [84, 163, 164], a highly scalable MD simulation
package that has been developed over the past two decades in the Shulten lab. Modeling and
analysis employed also the program VMD [88]. We use AMBER99SB force field [85, 86, 165] with
parameters for modified nucleosides [87].
MDFF simulations
The MDFF method [110, 111] is a hybrid approach [166] to integrate structural data from both high-
resolution X-ray crystallography and cryo-EM which only resolves low-resolution density envelopes
of biomolecules. MDFF overcomes the challenge of determining atomic-level structures of ribosomes
in different functional states [27, 28, 30, 31, 33, 38, 114, 167–175].
UMDFF(
−→
R ) = UMD + Ucryo−EMdensity (A.3)
As shown in Eq. A.3, in addition to the potential contribution by normal MD force fields (UMD),
the second term incorporates the EM density as a potential (Ucryo−EMdensity), which exerts on every
atom additional forces proportional to the gradient of the EM map, so that atoms in the structure
of a biomolecule tend to move into the density envelope during MD simulations. The resulting
conformation of a structure in an MDFF simulation can be an accurate interpretation of the cryo-
EM map with atomic resolution.
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